1
|
Zhang J, Hu X, Wang T, Xiao R, Zhu L, Ruiz M, Dupuis J, Hu Q. Extracellular vesicles in venous thromboembolism and pulmonary hypertension. J Nanobiotechnology 2023; 21:461. [PMID: 38037042 PMCID: PMC10691137 DOI: 10.1186/s12951-023-02216-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Accepted: 11/15/2023] [Indexed: 12/02/2023] Open
Abstract
Venous thromboembolism (VTE) is a multifactorial disease, and pulmonary hypertension (PH) is a serious condition characterized by pulmonary vascular remodeling leading with increased pulmonary vascular resistance, ultimately leading to right heart failure and death. Although VTE and PH have distinct primary etiologies, they share some pathophysiologic similarities such as dysfunctional vasculature and thrombosis. In both conditions there is solid evidence that EVs derived from a variety of cell types including platelets, monocytes, endothelial cells and smooth muscle cells contribute to vascular endothelial dysfunction, inflammation, thrombosis, cellular activation and communications. However, the roles and importance of EVs substantially differ between studies depending on experimental conditions and parent cell origins of EVs that modify the nature of their cargo. Numerous studies have confirmed that EVs contribute to the pathophysiology of VTE and PH and increased levels of various EVs in relation with the severity of VTE and PH, confirming its potential pathophysiological role and its utility as a biomarker of disease severity and as potential therapeutic targets.
Collapse
Affiliation(s)
- Jiwei Zhang
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), 13 Hangkong Road, Wuhan, 430030, China
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China
- Department of Pathology, Union Hospital, Tongji Medical College, HUST, Wuhan, China
| | - Xiaoyi Hu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), 13 Hangkong Road, Wuhan, 430030, China
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China
- Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
| | - Tao Wang
- Department of Respiratory Medicine, Tongji Hospital, Tongji Medical College, HUST, Wuhan, China
| | - Rui Xiao
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), 13 Hangkong Road, Wuhan, 430030, China
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China
| | - Liping Zhu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), 13 Hangkong Road, Wuhan, 430030, China
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China
| | - Matthieu Ruiz
- Department of Nutrition, Université de Montréal, Montreal, Canada
- Montreal Heart Institute, Montréal, Québec, Canada
| | - Jocelyn Dupuis
- Montreal Heart Institute, Montréal, Québec, Canada
- Department of Medicine, Université de Montréal, Montréal, Québec, Canada
| | - Qinghua Hu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), 13 Hangkong Road, Wuhan, 430030, China.
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China.
| |
Collapse
|
2
|
Yu D, Zhang T, Zhou G, Wu Z, Xiao R, Zhang H, Liu B, Li X, Ruiz M, Dupuis J, Zhu L, Hu Q. Co-profiling reveals distinct patterns of genomic chromatin accessibility and gene expression in pulmonary hypertension caused by chronic hypoxia. Respir Res 2023; 24:104. [PMID: 37031175 PMCID: PMC10082509 DOI: 10.1186/s12931-023-02389-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Accepted: 03/08/2023] [Indexed: 04/10/2023] Open
Abstract
INTRODUCTION Aberrant gene expression is a key mechanism underlying pulmonary hypertension (PH) development. The alterations of genomic chromatin accessibility and their relationship with the aberrant gene expressions in PH are poorly understood. We used bulk Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq) and RNA sequencing (RNA-seq) in pulmonary artery smooth muscle cells (PASMCs) of chronic hypoxia-exposed rats mimicking group 3 human PH. METHODS Adult Sprague Dawley rats were commercially obtained from Hunan SJA (Hunan SJA Laboratory Animal Co., Changsha, China) and randomizedly allocated into four groups exposing to nomobaric hypoxia or normoxia for 1 or 28 days respectively. After the assessment of pulmonary hemodynamics, smooth muscle cells were isolated from intralobular arteries and simultaneously subjected to bulk Assay of ATAC-seq and RNA-seq. RESULTS Hypoxic exposure for continuous 28-days, but not for 1-day, induced established PH phenotypes in rats. ATAC-seq revealed a major distribution of differential accessibility regions (DARs) annotated to the genome in out-of-promoter regions, following 1-day or 28-days hypoxia. 1188 DAR-associated genes and 378 differentially expressed genes (DEGs) were identified in rats after exposure to 1-day hypoxia, while 238 DAR-associated genes and 452 DEGs for 28-days hypoxia. Most of the DAR-associated genes or DEGs in 1-day did not overlap with that of 28-days hypoxia. A Pearson correlation analysis indicated no significant correlation between ATAC-seq and RNA-seq. CONCLUSIONS The alterations in genomic chromatin accessibility and genes expression of PASMCs in the initial stage of hypoxia are distinct from the established stage of hypoxia-induced PH. The genomic differential accessibility regions may not be the main mechanisms directly underlying the differentially expressed genes observed either in the initial or established stages of PH. Thus the time-course alterations of gene expression and their possible indirect link with genomic chromatin accessibility warrant more attention in mechanistic study of pulmonary hypertension.
Collapse
Affiliation(s)
- Dongdong Yu
- Department of Pathophysiology, School of Basic Medicine, Wuhan, China
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
- Department of Oncology, Renmin Hospital, Wuhan University, Wuhan, China
| | - Ting Zhang
- Department of Pathophysiology, School of Basic Medicine, Wuhan, China
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Guangyuan Zhou
- Department of Pathophysiology, School of Basic Medicine, Wuhan, China
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Zeang Wu
- Department of Pathophysiology, School of Basic Medicine, Wuhan, China
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Rui Xiao
- Department of Pathophysiology, School of Basic Medicine, Wuhan, China
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Han Zhang
- Department of Pathophysiology, School of Basic Medicine, Wuhan, China
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Bingxun Liu
- Department of Pathophysiology, School of Basic Medicine, Wuhan, China
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Xiangpan Li
- Department of Oncology, Renmin Hospital, Wuhan University, Wuhan, China
| | - Matthieu Ruiz
- Department of Nutrition, Université de Montréal, Montreal, Canada
- Montreal Heart Institute, Montreal, QC, Canada
| | - Jocelyn Dupuis
- Montreal Heart Institute, Montreal, QC, Canada
- Department of Medicine, Université de Montréal, Montreal, QC, Canada
| | - Liping Zhu
- Department of Pathophysiology, School of Basic Medicine, Wuhan, China
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Qinghua Hu
- Department of Pathophysiology, School of Basic Medicine, Wuhan, China.
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
| |
Collapse
|
3
|
Nasri A, Dupuis J, Carrier M, Racine N, Parent MC, Ducharme A, Fortier A, Hausermann L, White M, Tremblay-Gravel M. Thirty-year trends and outcome of isolated versus combined group 2 pulmonary hypertension after cardiac transplantation. Front Cardiovasc Med 2022; 9:841025. [DOI: 10.3389/fcvm.2022.841025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 11/16/2022] [Indexed: 12/03/2022] Open
Abstract
AimTo investigate the effect of the new definition of pulmonary hypertension (PH) and new pulmonary vascular resistance (PVR) thresholds on the prevalence, clinical characteristics, and events following cardiac transplantation (CTx) over 30 years.MethodsPatients who underwent CTx between 1983 and 2014 for whom invasive hemodynamic data was available were analyzed (n = 342). Patients transplanted between 1983 and 1998 were classified as early era and those transplanted between 1999 and 2014 were classified as recent era. Group 2 PH was diagnosed in the presence of a mean pulmonary artery pressure (mPAP) > 20 mmHg and pulmonary capillary wedge pressure (PCWP) > 15 mmHg. Isolated post capillary PH (Ipc-PH) was defined as PVR ≤ 2 wood units and combined pre and post capillary PH (Cpc-PH) was defined PVR > 2 wood units. Moderate to severe PH was defined as mPAP ≥ 35 mmHg. The primary outcome was 30-day mortality and long-term mortality according to type and severity of PH. Proportions were analyzed using the chi-square test, and survival analyses were performed using Kaplan-Meier curves and compared using the logrank test.ResultsThe prevalence of PH in patients transplanted in the early era was 89.1%, whilst 84.2% of patients transplanted in the recent era had PH (p = 0.3914). There was no difference in the prevalence of a pre-capillary component according to era (p = 0.4001), but severe PH was more common in the early era (51.1% [early] vs 38.0% [recent] p = 0.0151). Thirty-day and long-term mortality were not significantly associated with severity or type of PH. There was a trend toward increased 30-day mortality in mild PH (10.1%), compared to no PH (4.4%) and moderate to severe PH (6.6%; p = 0.0653). Long-term mortality did not differ according to the severity of PH (p = 0.1480). There were no significant differences in 30-day or long-term mortality in IpcPH compared to CpcPH (p = 0.3974 vs p = 0.5767, respectively).ConclusionOver 30 years, PH has remained very prevalent before CTx. The presence, severity, and type (pre- vs post-capillary) of PH is not significantly associated with short- or long-term mortality.
Collapse
|
4
|
Su Y, Tan R, Sun M, Yuan L, Ruiz M, Dupuis J, Hu Q, Zhu L. MiR-1249 on Endothelial Extracellular Vesicles Mediates Cigarette Smoke–Induced Pulmonary Hypertension by Inhibiting HDAC10 (Histone Deacetylase 10)-NFκB (Nuclear Factor κB)-CaSR (Calcium Sensitive Receptors) Cascade. Hypertension 2022; 79:2721-2732. [DOI: 10.1161/hypertensionaha.122.19560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
Overproduction of endothelial extracellular vesicles (eEVs) is correlated with pulmonary hypertension progression, but the precise mechanism remains largely unclear.
Methods:
MicroRNA-chip and real-time polymerase chain reaction real-time polymerase chain reaction were conducted to screen and validate microRNA profiles in blood plasma eEVs of rats and human with or without cigarette smoking. Pulmonary artery smooth muscle cells were cultured to study signaling pathways. Pulmonary hypertension phenotypes were evaluated in wild-type and calcium-sensing receptor knockout rats to identify the pathophysiological significance of the microRNA pathway.
Results:
MicroR-1249 was predominant highly expressed in eEVs from plasma of rats exposed to cigarette smoking, and confirmed in eEVs from plasma of human smokers as well as in eEVs from cigarette smoke extract-treated pulmonary artery endothelial cells, but not in cigarette smoke extract-treated pulmonary artery smooth muscle cells. In cultured pulmonary artery smooth muscle cells, microR-1249 downregulated the expression of histone deacetylase 10, which in turn enhanced the acetylated form of NFκB (nuclear factor κB) level and its nuclear translocation leading to increased expression of calcium-sensing receptor. In rats, the repression of microR-1249 in eEVs by microR-1249 inhibitor, histone deacetylase 10 overexpression, or calcium-sensing receptor knockout profoundly inhibited the proliferative capacities and diminished apoptosis-resistance of pulmonary artery smooth muscle cells and pulmonary hypertension development in rats intravenously administrated with eEVs preparation from cigarette smoke extract-treated pulmonary artery endothelial cells.
Conclusions:
Cigarette smoke–enriched microR-1249 in endothelial extracellular vesicles facilitates the hyperproliferative and antiapoptotic status of pulmonary artery smooth muscle cells promoting pulmonary hypertension evolution through the inhibition of histone deacetylase 10–NFκB–calcium-sensing receptor cascade.
Collapse
Affiliation(s)
- Yuan Su
- Department of Pathophysiology, School of Basic Medicine, and Key Laboratory of Pulmonary Diseases of Ministry of Health (Y.S., R.T., M.S., Q.H., L.Z.)
- Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (Y.S.)
| | - Rubin Tan
- Department of Pathophysiology, School of Basic Medicine, and Key Laboratory of Pulmonary Diseases of Ministry of Health (Y.S., R.T., M.S., Q.H., L.Z.)
- Department of Physiology, Xuzhou Medical University, China (R.T.)
| | - Mengxiang Sun
- Department of Pathophysiology, School of Basic Medicine, and Key Laboratory of Pulmonary Diseases of Ministry of Health (Y.S., R.T., M.S., Q.H., L.Z.)
| | - Linbo Yuan
- Department of Physiology, Wenzhou Medical University, China (L.Y.)
| | - Matthieu Ruiz
- Department of Nutrition, Université de Montréal, Canada. (M.R.)
- Montreal Heart Institute, Montreal, Canada (M.R., J.D.)
| | - Jocelyn Dupuis
- Department of Medicine, Université de Montréal, Canada. (J.D.)
- Montreal Heart Institute, Montreal, Canada (M.R., J.D.)
| | - Qinghua Hu
- Department of Pathophysiology, School of Basic Medicine, and Key Laboratory of Pulmonary Diseases of Ministry of Health (Y.S., R.T., M.S., Q.H., L.Z.)
| | - Liping Zhu
- Department of Pathophysiology, School of Basic Medicine, and Key Laboratory of Pulmonary Diseases of Ministry of Health (Y.S., R.T., M.S., Q.H., L.Z.)
| |
Collapse
|
5
|
Xiao R, Liu J, Luo S, Yu Z, Zhang J, Lv Y, Li J, Ruiz M, Dupuis J, Hu Q, Zhu L. Orally-administrated mitochondria attenuate pulmonary hypertension with the aid of erythrocytes as carriers. Clin Transl Med 2022; 12:e1033. [PMID: 36149749 PMCID: PMC9505751 DOI: 10.1002/ctm2.1033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Revised: 08/05/2022] [Accepted: 08/09/2022] [Indexed: 11/05/2022] Open
Affiliation(s)
- Rui Xiao
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jie Liu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Shengquan Luo
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Zhe Yu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jiwei Zhang
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yankai Lv
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jiansha Li
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Matthieu Ruiz
- Department of Nutrition, Université de Montréal, Montreal, Canada.,Montreal Heart Institute, Montreal, Canada
| | - Jocelyn Dupuis
- Montreal Heart Institute, Montreal, Canada.,Department of medicine, Université de Montréal, Montreal, Canada
| | - Qinghua Hu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Liping Zhu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
6
|
Deshmukh A, Kesari P, Pahelkar N, Suryawanshi A, Rathore I, Mishra V, Dupuis J, Xiao H, Gustchina A, Abendroth J, Labaied M, Yada R, Wlodawer A, Edwards T, Lorimer D, Bhaumik P. Structural insights of plasmepsin X from Plasmodium falciparum uncovering a novel inactivation mechanism of zymogen. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322093470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
7
|
Proietti M, Romiti GF, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, Näbauer M, Potpara TS, Dan GA, Maggioni AP, Cesari M, Boriani G, Lip GYH, Ekmekçiu U, Paparisto V, Tase M, Gjergo H, Dragoti J, Goda A, Ciutea M, Ahadi N, el Husseini Z, Raepers M, Leroy J, Haushan P, Jourdan A, Lepiece C, Desteghe L, Vijgen J, Koopman P, Van Genechten G, Heidbuchel H, Boussy T, De Coninck M, Van Eeckhoutte H, Bouckaert N, Friart A, Boreux J, Arend C, Evrard P, Stefan L, Hoffer E, Herzet J, Massoz M, Celentano C, Sprynger M, Pierard L, Melon P, Van Hauwaert B, Kuppens C, Faes D, Van Lier D, Van Dorpe A, Gerardy A, Deceuninck O, Xhaet O, Dormal F, Ballant E, Blommaert D, Yakova D, Hristov M, Yncheva T, Stancheva N, Tisheva S, Tokmakova M, Nikolov F, Gencheva D, Shalganov T, Kunev B, Stoyanov M, Marchov D, Gelev V, Traykov V, Kisheva A, Tsvyatkov H, Shtereva R, Bakalska-Georgieva S, Slavcheva S, Yotov Y, Kubíčková M, Marni Joensen A, Gammelmark A, Hvilsted Rasmussen L, Dinesen P, Riahi S, Krogh Venø S, Sorensen B, Korsgaard A, Andersen K, Fragtrup Hellum C, Svenningsen A, Nyvad O, Wiggers P, May O, Aarup A, Graversen B, Jensen L, Andersen M, Svejgaard M, Vester S, Hansen S, Lynggaard V, Ciudad M, Vettus R, Muda P, Maestre A, Castaño S, Cheggour S, Poulard J, Mouquet V, Leparrée S, Bouet J, Taieb J, Doucy A, Duquenne H, Furber A, Dupuis J, Rautureau J, Font M, Damiano P, Lacrimini M, Abalea J, Boismal S, Menez T, Mansourati J, Range G, Gorka H, Laure C, Vassalière C, Elbaz N, Lellouche N, Djouadi K, Roubille F, Dietz D, Davy J, Granier M, Winum P, Leperchois-Jacquey C, Kassim H, Marijon E, Le Heuzey J, Fedida J, Maupain C, Himbert C, Gandjbakhch E, Hidden-Lucet F, Duthoit G, Badenco N, Chastre T, Waintraub X, Oudihat M, Lacoste J, Stephan C, Bader H, Delarche N, Giry L, Arnaud D, Lopez C, Boury F, Brunello I, Lefèvre M, Mingam R, Haissaguerre M, Le Bidan M, Pavin D, Le Moal V, Leclercq C, Piot O, Beitar T, Martel I, Schmid A, Sadki N, Romeyer-Bouchard C, Da Costa A, Arnault I, Boyer M, Piat C, Fauchier L, Lozance N, Nastevska S, Doneva A, Fortomaroska Milevska B, Sheshoski B, Petroska K, Taneska N, Bakrecheski N, Lazarovska K, Jovevska S, Ristovski V, Antovski A, Lazarova E, Kotlar I, Taleski J, Poposka L, Kedev S, Zlatanovik N, Jordanova S, Bajraktarova Proseva T, Doncovska S, Maisuradze D, Esakia A, Sagirashvili E, Lartsuliani K, Natelashvili N, Gumberidze N, Gvenetadze R, Etsadashvili K, Gotonelia N, Kuridze N, Papiashvili G, Menabde I, Glöggler S, Napp A, Lebherz C, Romero H, Schmitz K, Berger M, Zink M, Köster S, Sachse J, Vonderhagen E, Soiron G, Mischke K, Reith R, Schneider M, Rieker W, Boscher D, Taschareck A, Beer A, Oster D, Ritter O, Adamczewski J, Walter S, Frommhold A, Luckner E, Richter J, Schellner M, Landgraf S, Bartholome S, Naumann R, Schoeler J, Westermeier D, William F, Wilhelm K, Maerkl M, Oekinghaus R, Denart M, Kriete M, Tebbe U, Scheibner T, Gruber M, Gerlach A, Beckendorf C, Anneken L, Arnold M, Lengerer S, Bal Z, Uecker C, Förtsch H, Fechner S, Mages V, Martens E, Methe H, Schmidt T, Schaeffer B, Hoffmann B, Moser J, Heitmann K, Willems S, Willems S, Klaus C, Lange I, Durak M, Esen E, Mibach F, Mibach H, Utech A, Gabelmann M, Stumm R, Ländle V, Gartner C, Goerg C, Kaul N, Messer S, Burkhardt D, Sander C, Orthen R, Kaes S, Baumer A, Dodos F, Barth A, Schaeffer G, Gaertner J, Winkler J, Fahrig A, Aring J, Wenzel I, Steiner S, Kliesch A, Kratz E, Winter K, Schneider P, Haag A, Mutscher I, Bosch R, Taggeselle J, Meixner S, Schnabel A, Shamalla A, Hötz H, Korinth A, Rheinert C, Mehltretter G, Schön B, Schön N, Starflinger A, Englmann E, Baytok G, Laschinger T, Ritscher G, Gerth A, Dechering D, Eckardt L, Kuhlmann M, Proskynitopoulos N, Brunn J, Foth K, Axthelm C, Hohensee H, Eberhard K, Turbanisch S, Hassler N, Koestler A, Stenzel G, Kschiwan D, Schwefer M, Neiner S, Hettwer S, Haeussler-Schuchardt M, Degenhardt R, Sennhenn S, Steiner S, Brendel M, Stoehr A, Widjaja W, Loehndorf S, Logemann A, Hoskamp J, Grundt J, Block M, Ulrych R, Reithmeier A, Panagopoulos V, Martignani C, Bernucci D, Fantecchi E, Diemberger I, Ziacchi M, Biffi M, Cimaglia P, Frisoni J, Boriani G, Giannini I, Boni S, Fumagalli S, Pupo S, Di Chiara A, Mirone P, Fantecchi E, Boriani G, Pesce F, Zoccali C, Malavasi VL, Mussagaliyeva A, Ahyt B, Salihova Z, Koshum-Bayeva K, Kerimkulova A, Bairamukova A, Mirrakhimov E, Lurina B, Zuzans R, Jegere S, Mintale I, Kupics K, Jubele K, Erglis A, Kalejs O, Vanhear K, Burg M, Cachia M, Abela E, Warwicker S, Tabone T, Xuereb R, Asanovic D, Drakalovic D, Vukmirovic M, Pavlovic N, Music L, Bulatovic N, Boskovic A, Uiterwaal H, Bijsterveld N, De Groot J, Neefs J, van den Berg N, Piersma F, Wilde A, Hagens V, Van Es J, Van Opstal J, Van Rennes B, Verheij H, Breukers W, Tjeerdsma G, Nijmeijer R, Wegink D, Binnema R, Said S, Erküner Ö, Philippens S, van Doorn W, Crijns H, Szili-Torok T, Bhagwandien R, Janse P, Muskens A, van Eck M, Gevers R, van der Ven N, Duygun A, Rahel B, Meeder J, Vold A, Holst Hansen C, Engset I, Atar D, Dyduch-Fejklowicz B, Koba E, Cichocka M, Sokal A, Kubicius A, Pruchniewicz E, Kowalik-Sztylc A, Czapla W, Mróz I, Kozlowski M, Pawlowski T, Tendera M, Winiarska-Filipek A, Fidyk A, Slowikowski A, Haberka M, Lachor-Broda M, Biedron M, Gasior Z, Kołodziej M, Janion M, Gorczyca-Michta I, Wozakowska-Kaplon B, Stasiak M, Jakubowski P, Ciurus T, Drozdz J, Simiera M, Zajac P, Wcislo T, Zycinski P, Kasprzak J, Olejnik A, Harc-Dyl E, Miarka J, Pasieka M, Ziemińska-Łuć M, Bujak W, Śliwiński A, Grech A, Morka J, Petrykowska K, Prasał M, Hordyński G, Feusette P, Lipski P, Wester A, Streb W, Romanek J, Woźniak P, Chlebuś M, Szafarz P, Stanik W, Zakrzewski M, Kaźmierczak J, Przybylska A, Skorek E, Błaszczyk H, Stępień M, Szabowski S, Krysiak W, Szymańska M, Karasiński J, Blicharz J, Skura M, Hałas K, Michalczyk L, Orski Z, Krzyżanowski K, Skrobowski A, Zieliński L, Tomaszewska-Kiecana M, Dłużniewski M, Kiliszek M, Peller M, Budnik M, Balsam P, Opolski G, Tymińska A, Ozierański K, Wancerz A, Borowiec A, Majos E, Dabrowski R, Szwed H, Musialik-Lydka A, Leopold-Jadczyk A, Jedrzejczyk-Patej E, Koziel M, Lenarczyk R, Mazurek M, Kalarus Z, Krzemien-Wolska K, Starosta P, Nowalany-Kozielska E, Orzechowska A, Szpot M, Staszel M, Almeida S, Pereira H, Brandão Alves L, Miranda R, Ribeiro L, Costa F, Morgado F, Carmo P, Galvao Santos P, Bernardo R, Adragão P, Ferreira da Silva G, Peres M, Alves M, Leal M, Cordeiro A, Magalhães P, Fontes P, Leão S, Delgado A, Costa A, Marmelo B, Rodrigues B, Moreira D, Santos J, Santos L, Terchet A, Darabantiu D, Mercea S, Turcin Halka V, Pop Moldovan A, Gabor A, Doka B, Catanescu G, Rus H, Oboroceanu L, Bobescu E, Popescu R, Dan A, Buzea A, Daha I, Dan G, Neuhoff I, Baluta M, Ploesteanu R, Dumitrache N, Vintila M, Daraban A, Japie C, Badila E, Tewelde H, Hostiuc M, Frunza S, Tintea E, Bartos D, Ciobanu A, Popescu I, Toma N, Gherghinescu C, Cretu D, Patrascu N, Stoicescu C, Udroiu C, Bicescu G, Vintila V, Vinereanu D, Cinteza M, Rimbas R, Grecu M, Cozma A, Boros F, Ille M, Tica O, Tor R, Corina A, Jeewooth A, Maria B, Georgiana C, Natalia C, Alin D, Dinu-Andrei D, Livia M, Daniela R, Larisa R, Umaar S, Tamara T, Ioachim Popescu M, Nistor D, Sus I, Coborosanu O, Alina-Ramona N, Dan R, Petrescu L, Ionescu G, Popescu I, Vacarescu C, Goanta E, Mangea M, Ionac A, Mornos C, Cozma D, Pescariu S, Solodovnicova E, Soldatova I, Shutova J, Tjuleneva L, Zubova T, Uskov V, Obukhov D, Rusanova G, Soldatova I, Isakova N, Odinsova S, Arhipova T, Kazakevich E, Serdechnaya E, Zavyalova O, Novikova T, Riabaia I, Zhigalov S, Drozdova E, Luchkina I, Monogarova Y, Hegya D, Rodionova L, Rodionova L, Nevzorova V, Soldatova I, Lusanova O, Arandjelovic A, Toncev D, Milanov M, Sekularac N, Zdravkovic M, Hinic S, Dimkovic S, Acimovic T, Saric J, Polovina M, Potpara T, Vujisic-Tesic B, Nedeljkovic M, Zlatar M, Asanin M, Vasic V, Popovic Z, Djikic D, Sipic M, Peric V, Dejanovic B, Milosevic N, Stevanovic A, Andric A, Pencic B, Pavlovic-Kleut M, Celic V, Pavlovic M, Petrovic M, Vuleta M, Petrovic N, Simovic S, Savovic Z, Milanov S, Davidovic G, Iric-Cupic V, Simonovic D, Stojanovic M, Stojanovic S, Mitic V, Ilic V, Petrovic D, Deljanin Ilic M, Ilic S, Stoickov V, Markovic S, Kovacevic S, García Fernandez A, Perez Cabeza A, Anguita M, Tercedor Sanchez L, Mau E, Loayssa J, Ayarra M, Carpintero M, Roldán Rabadan I, Leal M, Gil Ortega M, Tello Montoliu A, Orenes Piñero E, Manzano Fernández S, Marín F, Romero Aniorte A, Veliz Martínez A, Quintana Giner M, Ballesteros G, Palacio M, Alcalde O, García-Bolao I, Bertomeu Gonzalez V, Otero-Raviña F, García Seara J, Gonzalez Juanatey J, Dayal N, Maziarski P, Gentil-Baron P, Shah D, Koç M, Onrat E, Dural IE, Yilmaz K, Özin B, Tan Kurklu S, Atmaca Y, Canpolat U, Tokgozoglu L, Dolu AK, Demirtas B, Sahin D, Ozcan Celebi O, Diker E, Gagirci G, Turk UO, Ari H, Polat N, Toprak N, Sucu M, Akin Serdar O, Taha Alper A, Kepez A, Yuksel Y, Uzunselvi A, Yuksel S, Sahin M, Kayapinar O, Ozcan T, Kaya H, Yilmaz MB, Kutlu M, Demir M, Gibbs C, Kaminskiene S, Bryce M, Skinner A, Belcher G, Hunt J, Stancombe L, Holbrook B, Peters C, Tettersell S, Shantsila A, Lane D, Senoo K, Proietti M, Russell K, Domingos P, Hussain S, Partridge J, Haynes R, Bahadur S, Brown R, McMahon S, Y H Lip G, McDonald J, Balachandran K, Singh R, Garg S, Desai H, Davies K, Goddard W, Galasko G, Rahman I, Chua Y, Payne O, Preston S, Brennan O, Pedley L, Whiteside C, Dickinson C, Brown J, Jones K, Benham L, Brady R, Buchanan L, Ashton A, Crowther H, Fairlamb H, Thornthwaite S, Relph C, McSkeane A, Poultney U, Kelsall N, Rice P, Wilson T, Wrigley M, Kaba R, Patel T, Young E, Law J, Runnett C, Thomas H, McKie H, Fuller J, Pick S, Sharp A, Hunt A, Thorpe K, Hardman C, Cusack E, Adams L, Hough M, Keenan S, Bowring A, Watts J, Zaman J, Goffin K, Nutt H, Beerachee Y, Featherstone J, Mills C, Pearson J, Stephenson L, Grant S, Wilson A, Hawksworth C, Alam I, Robinson M, Ryan S, Egdell R, Gibson E, Holland M, Leonard D, Mishra B, Ahmad S, Randall H, Hill J, Reid L, George M, McKinley S, Brockway L, Milligan W, Sobolewska J, Muir J, Tuckis L, Winstanley L, Jacob P, Kaye S, Morby L, Jan A, Sewell T, Boos C, Wadams B, Cope C, Jefferey P, Andrews N, Getty A, Suttling A, Turner C, Hudson K, Austin R, Howe S, Iqbal R, Gandhi N, Brophy K, Mirza P, Willard E, Collins S, Ndlovu N, Subkovas E, Karthikeyan V, Waggett L, Wood A, Bolger A, Stockport J, Evans L, Harman E, Starling J, Williams L, Saul V, Sinha M, Bell L, Tudgay S, Kemp S, Brown J, Frost L, Ingram T, Loughlin A, Adams C, Adams M, Hurford F, Owen C, Miller C, Donaldson D, Tivenan H, Button H, Nasser A, Jhagra O, Stidolph B, Brown C, Livingstone C, Duffy M, Madgwick P, Roberts P, Greenwood E, Fletcher L, Beveridge M, Earles S, McKenzie D, Beacock D, Dayer M, Seddon M, Greenwell D, Luxton F, Venn F, Mills H, Rewbury J, James K, Roberts K, Tonks L, Felmeden D, Taggu W, Summerhayes A, Hughes D, Sutton J, Felmeden L, Khan M, Walker E, Norris L, O’Donohoe L, Mozid A, Dymond H, Lloyd-Jones H, Saunders G, Simmons D, Coles D, Cotterill D, Beech S, Kidd S, Wrigley B, Petkar S, Smallwood A, Jones R, Radford E, Milgate S, Metherell S, Cottam V, Buckley C, Broadley A, Wood D, Allison J, Rennie K, Balian L, Howard L, Pippard L, Board S, Pitt-Kerby T. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing 2022; 51:6670566. [PMID: 35997262 DOI: 10.1093/ageing/afac192] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 06/08/2022] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Frailty is a medical syndrome characterised by reduced physiological reserve and increased vulnerability to stressors. Data regarding the relationship between frailty and atrial fibrillation (AF) are still inconsistent. OBJECTIVES We aim to perform a comprehensive evaluation of frailty in a large European cohort of AF patients. METHODS A 40-item frailty index (FI) was built according to the accumulation of deficits model in the AF patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. Association of baseline characteristics, clinical management, quality of life, healthcare resources use and risk of outcomes with frailty was examined. RESULTS Among 10,177 patients [mean age (standard deviation) 69.0 (11.4) years, 4,103 (40.3%) females], 6,066 (59.6%) were pre-frail and 2,172 (21.3%) were frail, whereas only 1,939 (19.1%) were considered robust. Baseline thromboembolic and bleeding risks were independently associated with increasing FI. Frail patients with AF were less likely to be treated with oral anticoagulants (OACs) (odds ratio 0.70, 95% confidence interval 0.55-0.89), especially with non-vitamin K antagonist OACs and managed with a rhythm control strategy, compared with robust patients. Increasing frailty was associated with a higher risk for all outcomes examined, with a non-linear exponential relationship. The use of OAC was associated with a lower risk of outcomes, except in patients with very/extremely high frailty. CONCLUSIONS In this large cohort of AF patients, there was a high burden of frailty, influencing clinical management and risk of adverse outcomes. The clinical benefit of OAC is maintained in patients with high frailty, but not in very high/extremely frail ones.
Collapse
Affiliation(s)
- Marco Proietti
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.,Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
| | - Giulio Francesco Romiti
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Translational and Precision Medicine, Sapienza - University of Rome, Italy
| | - Marco Vitolo
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.,Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
| | - Stephanie L Harrison
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK
| | - Deirdre A Lane
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Laurent Fauchier
- Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France
| | - Francisco Marin
- Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, CIBER-CV, Murcia, Spain
| | - Michael Näbauer
- Department of Cardiology, Ludwig-Maximilians-University, Munich, Germany
| | - Tatjana S Potpara
- School of Medicine, University of Belgrade, Belgrade, Serbia.,Clinical Center of Serbia, Belgrade, Serbia
| | - Gheorghe-Andrei Dan
- University of Medicine, 'Carol Davila', Colentina University Hospital, Bucharest, Romania
| | - Aldo P Maggioni
- ANMCO Research Center, Heart Care Foundation, Florence, Italy
| | - Matteo Cesari
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.,Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
| | - Giuseppe Boriani
- Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
| | - Gregory Y H Lip
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Liu B, Wei YP, Fan X, Hu X, Chen Z, Liu X, Xu Y, Wang L, Wang T, Ruiz M, Dupuis J, Yuan P, Liu J, Huang S, Zhu L, Jing ZC, Hu Q. Calcium Sensing Receptor Variants Increase Pulmonary Hypertension Susceptibility. Hypertension 2022; 79:1348-1360. [PMID: 35477244 DOI: 10.1161/hypertensionaha.121.18399] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Pulmonary arterial hypertension is an incurable disease, in which the extracellular CaSR (calcium sensing receptor) is mechanistically important. This study was aimed to genetically link the CaSR gene and function to the disease severity. METHODS Sanger sequencing, Sugen/hypoxia pulmonary arterial hypertension rat model, CaSR mutated rat, transcriptional reporter assay and measurement of CaSR activity were used. RESULTS Sanger sequencing identified a significant association between the variant rs1042636(A>G), located in CaSR exon 7, and idiopathic pulmonary arterial hypertension (IPAH) formation in patients. The frequency of 2968G homozygotes was higher in patients with IPAH compared with healthy individuals (23.6% versus 17.5%; P=0.001, OR=1.864), and the minor alleles of rs6776158, rs1048213, and rs9883099, located in CaSR promoter, raised the IPAH odds ratio to 2.173. Patients with IPAH carrying heterozygotes or homozygotes genotype of rs1042636 showed markedly higher pulmonary artery pressure and reduced survival compared with individuals carrying the wild-type allele. The minor alleles of rs6776158, rs1048213, and rs9883099 increased CaSR expression in reporter assay. In Sugen/hypoxia pulmonary arterial hypertension rats, the point mutation replicating rs1042636 found in IPAH exacerbated pulmonary arterial hypertension severity by promoting the overexpression and the enhanced activity of CaSR. CONCLUSIONS Our functional genomic analysis thus indicates that the CaSR minor alleles of rs1042636, rs6776158, rs1048213, and rs9883099 contribute to the development and severity of IPAH. These findings may benefit clinical prognosis and treatment for IPAH.
Collapse
Affiliation(s)
- Bingxun Liu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China (B.L., X.F., Z.C., X.L.,Y.X., L.Z., Q.H.)
| | - Yun-Peng Wei
- Department of Cardiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.-P.W., Z.-C.J.)
| | - Xiaohang Fan
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China (B.L., X.F., Z.C., X.L.,Y.X., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China (B.X., X.F., X.H., Z.C., X.L., Y.X., L.W., T.W., L.Z., Q.H.)
| | - Xiaoyi Hu
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China (B.X., X.F., X.H., Z.C., X.L., Y.X., L.W., T.W., L.Z., Q.H.).,Department of Respiratory and Critical Care Medicine, Tongji Hospital; Tongji Medical College, HUST, Wuhan, China (X.H., L.W., T.W.)
| | - Zeshuai Chen
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China (B.L., X.F., Z.C., X.L.,Y.X., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China (B.X., X.F., X.H., Z.C., X.L., Y.X., L.W., T.W., L.Z., Q.H.)
| | - Xiaoyuan Liu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China (B.L., X.F., Z.C., X.L.,Y.X., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China (B.X., X.F., X.H., Z.C., X.L., Y.X., L.W., T.W., L.Z., Q.H.)
| | - Yan Xu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China (B.L., X.F., Z.C., X.L.,Y.X., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China (B.X., X.F., X.H., Z.C., X.L., Y.X., L.W., T.W., L.Z., Q.H.)
| | - Lu Wang
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China (B.X., X.F., X.H., Z.C., X.L., Y.X., L.W., T.W., L.Z., Q.H.).,Department of Respiratory and Critical Care Medicine, Tongji Hospital; Tongji Medical College, HUST, Wuhan, China (X.H., L.W., T.W.)
| | - Tao Wang
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China (B.X., X.F., X.H., Z.C., X.L., Y.X., L.W., T.W., L.Z., Q.H.).,Department of Respiratory and Critical Care Medicine, Tongji Hospital; Tongji Medical College, HUST, Wuhan, China (X.H., L.W., T.W.)
| | - Matthieu Ruiz
- Department of Nutrition, Université de Montréal, Canada (M.R.).,Montreal Heart Institute, Québec, Canada (M.R., J.D.)
| | - Jocelyn Dupuis
- Montreal Heart Institute, Québec, Canada (M.R., J.D.).,Department of medicine, Université de Montréal, Québec, Canada (J.D.)
| | - Ping Yuan
- Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai' China (P.Y., J.L.)
| | - Jinming Liu
- Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai' China (P.Y., J.L.)
| | - Songling Huang
- Department of Clinical Laboratory, the First Affiliate Hospital of Kunming Medical University, Kunming, China (S.H.)
| | - Liping Zhu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China (B.L., X.F., Z.C., X.L.,Y.X., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China (B.X., X.F., X.H., Z.C., X.L., Y.X., L.W., T.W., L.Z., Q.H.)
| | - Zhi-Cheng Jing
- Department of Cardiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.-P.W., Z.-C.J.)
| | - Qinghua Hu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China (B.L., X.F., Z.C., X.L.,Y.X., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, HUST, Wuhan, China (B.X., X.F., X.H., Z.C., X.L., Y.X., L.W., T.W., L.Z., Q.H.)
| |
Collapse
|
9
|
Legris V, Thibault B, Dupuis J, White M, Asgar AW, Fortier A, Pitre C, Bouabdallaoui N, Henri C, O'Meara E, Ducharme A. Right ventricular function and its coupling to pulmonary circulation predicts exercise tolerance in systolic heart failure. ESC Heart Fail 2021; 9:450-464. [PMID: 34953062 PMCID: PMC8788036 DOI: 10.1002/ehf2.13726] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Revised: 10/31/2021] [Accepted: 11/11/2021] [Indexed: 12/05/2022] Open
Abstract
Aims Right ventricular (RV) dysfunction, pulmonary hypertension, and exercise intolerance have prognostic values, but their interrelation is not fully understood. We investigated how RV function alone and its coupling with pulmonary circulation (RV‐PA) predict cardio‐respiratory fitness in patients with heart failure and reduced ejection fraction (HFrEF). Methods and results The Evaluation of Resynchronization Therapy for Heart Failure (EARTH) study included 205 HFrEF patients with narrow (n = 85) and prolonged (n = 120) QRS duration undergoing implantable cardioverter defibrillator implantation. All patients underwent a comprehensive evaluation with exercise tolerance tests and echocardiography. We investigated the correlations at baseline between RV parameters {size, function [tricuspid annular plane systolic excursion (TAPSE), RV fractional area change (RV‐FAC), and RV myocardial performance index (RV‐MPI)], pulmonary artery systolic pressure (PASP), and tricuspid regurgitation}; left ventricular ejection fraction (LVEF), left ventricular end‐diastolic volume index (LVEDVi), and left atrial volume index (LAVi); and cardiopulmonary exercise test (CPET) [peak VO2, minute ventilation/carbon dioxide production (VE/VCO2), 6 min walk distance (6MWD), and submaximal exercise duration (SED)]. We also studied the relationship between RV‐PA coupling (TAPSE/PASP ratio) and echocardiographic parameters in patients with both data available. Univariate and multivariate linear regression models were used. Patients enrolled in EARTH (overall population) were mostly male (73.2%), mean age 61.0 ± 9.8 years, New York Heart Association class II–III (87.8%), mean LVEF of 26.6 ± 7.7%, and reduced peak VO2 (15.1 ± 4.6 mL/kg/min). Of these, 100 had both TAPSE and PASP available (TAPSE/PASP population): they exhibited higher BNP, wider QRS duration, larger LVEDVi, with more having tricuspid regurgitation compared with the 105 patients for whom these values were not available (all P < 0.05). RV‐FAC (β = 7.5), LAVi (β = −0.1), and sex (female, β = −1.9) predicted peak VO2 in the overall population (all P = 0.01). When available, TAPSE/PASP ratio was the only echocardiographic parameter associated with peak VO2 (β = 6.8; P < 0.01), a threshold ≤0.45 predicting a peak VO2 ≤ 14 mL/kg/min (0.39 for VO2 ≤ 12). RV‐MPI was the only echocardiographic parameter associated with ventilatory inefficiency (VE/VCO2) and 6MWD (β = 21.9 and β = −69.3, respectively, both P ≤ 0.01) in the overall population. In presence of TAPSE/PASP, it became an important predictor for those two CPET (β = −18.0 and β = 72.4, respectively, both P < 0.01), together with RV‐MPI (β = 18.5, P < 0.01) for VE/VCO2. Tricuspid regurgitation predicted SED (β = −3.2, P = 0.03). Conclusions Right ventricular function assessed by echocardiography (RV‐MPI and RV‐FAC) is closely associated with exercise tolerance in patients with HFrEF. When the TAPSE/PASP ratio is available, this marker of RV‐PA coupling becomes the stronger echocardiographic predictor of exercise capacity in this population, highlighting its potential role as a screening tool to identify patients with reduced exercise capacity and potentially triage them to formal peak VO2 and/or evaluation for advanced HF therapies.
Collapse
Affiliation(s)
- Valéry Legris
- Department of Medicine, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada
| | - Bernard Thibault
- Department of Medicine, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada
| | - Jocelyn Dupuis
- Department of Medicine, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada
| | - Michel White
- Department of Medicine, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada
| | - Anita W Asgar
- Department of Medicine, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada
| | - Annik Fortier
- Montreal Health Institute Coordinating Center (MHICC), Montreal, Quebec, Canada
| | - Céline Pitre
- Department of Medicine, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada
| | - Nadia Bouabdallaoui
- Department of Medicine, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada
| | - Christine Henri
- Department of Medicine, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada
| | - Eileen O'Meara
- Department of Medicine, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada
| | - Anique Ducharme
- Department of Medicine, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada
| | | |
Collapse
|
10
|
Xiao R, Luo S, Zhang T, Lv Y, Wang T, Zhang J, Su Y, Ruiz M, Dupuis J, Zhu L, Hu Q. Peptide Blocking Self-Polymerization of Extracellular Calcium-Sensing Receptor Attenuates Hypoxia-Induced Pulmonary Hypertension. Hypertension 2021; 78:1605-1616. [PMID: 34565182 DOI: 10.1161/hypertensionaha.120.16712] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Rui Xiao
- From the Department of Pathophysiology, School of Basic Medicine (R.X., S.L., T.Z., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.)
| | - Shengquan Luo
- From the Department of Pathophysiology, School of Basic Medicine (R.X., S.L., T.Z., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.)
| | - Ting Zhang
- From the Department of Pathophysiology, School of Basic Medicine (R.X., S.L., T.Z., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.)
| | - Yankai Lv
- Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.).,Department of Pathology (Y.L.), Tongji Hospital
| | - Tao Wang
- Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.).,Department of Respiratory and Critical Care Medicine (T.W.), Tongji Hospital
| | | | - Yuan Su
- Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.).,Department of Respiratory and Critical Care Medicine, Union Hospital (Y.S.)
| | - Matthieu Ruiz
- Tongji Medical College, Huazhong University of Science and Technology (HUST), China; Department of Nutrition, Université de Montréal, Canada (M.R.).,Montreal Heart Institute, Canada (M.R., J.D.)
| | - Jocelyn Dupuis
- Montreal Heart Institute, Canada (M.R., J.D.).,Department of medicine, Université de Montréal, Canada (J.D.)
| | - Liping Zhu
- From the Department of Pathophysiology, School of Basic Medicine (R.X., S.L., T.Z., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.)
| | - Qinghua Hu
- From the Department of Pathophysiology, School of Basic Medicine (R.X., S.L., T.Z., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.)
| |
Collapse
|
11
|
Harel F, Nguyen QT, Nsaibia MJ, Finnerty V, Morgan A, Sirois M, Villeneuve L, Calderone A, Bergeron A, Brochiero E, Tardif JC, Shi Y, Dupuis J. SPECT imaging of pulmonary vascular disease in bleomycin-induced lung fibrosis using a vascular endothelium tracer. Respir Res 2021; 22:240. [PMID: 34481508 PMCID: PMC8418741 DOI: 10.1186/s12931-021-01836-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 08/31/2021] [Indexed: 11/17/2022] Open
Abstract
Background Pulmonary hypertension (PH) complicating idiopathic pulmonary fibrosis (IPF) is associated to worse outcome. There is a great need for a non-invasive diagnostic modality to detect and evaluate the severity of pulmonary vascular disease (PVD). 99mTc-PulmoBind is a novel imaging agent that binds to the adrenomedullin (AM) receptor on the pulmonary microvascular endothelium. SPECT imaging employing the endothelial cell tracer 99mTc-PulmoBind was used to assess PVD associated with lung fibrosis. Methods Rats with selective right lung bleomycin-induced fibrosis were compared to control rats. SPECT imaging was performed after three weeks with 99mTc-PulmoBind and 99mTc-macroaggregates of albumin (MAA). PH and right ventricular (RV) function were assessed by echocardiography. Lung perfusion was evaluated by fluorescent microangiography. Lung AM receptor expression was measured by qPCR and by immunohistology. Relevance to human IPF was explored by measuring AM receptor expression in lung biopsies from IPF patients and healthy controls. Results The bleomycin group developed preferential right lung fibrosis with remodeling and reduced perfusion as assessed with fluorescent microangiography. These rats developed PH with RV hypertrophy and dysfunction. 99mTc-PulmoBind uptake was selectively reduced by 50% in the right lung and associated with reduced AM receptor expression, PH and RV hypertrophy. AM receptor was co-expressed with the endothelial cell protein CD31 in alveolar capillaries, and markedly reduced after bleomycin. Quantitative dynamic analysis of 99mTc-PulmoBind uptake in comparison to 99mTc-MAA revealed that the latter distributed only according to flow, with about 60% increased left lung uptake while left lung uptake of 99mTc-PulmoBind was not affected. Lung from human IPF patients showed important reduction in AM receptor expression closely associated with CD31. Conclusions SPECT imaging with 99mTc-PulmoBind detects PVD and its severity in bleomycin-induced lung fibrosis. Reduced AM receptor expression in human IPF supports further clinical development of this imaging approach. Supplementary Information The online version contains supplementary material available at 10.1186/s12931-021-01836-3.
Collapse
Affiliation(s)
- François Harel
- Montreal Heart Institute Research Center, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada.,Department of Radiology, Radio-Oncology and Nuclear Medicine, Faculty of Medicine, Université de Montréal, 2900 Edouard-Montpetit Boulevard, Montreal, QC, H3T 1J4, Canada
| | - Quang T Nguyen
- Montreal Heart Institute Research Center, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
| | - Mohamed J Nsaibia
- Montreal Heart Institute Research Center, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
| | - Vincent Finnerty
- Montreal Heart Institute Research Center, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
| | - Arielle Morgan
- Montreal Heart Institute Research Center, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
| | - Martin Sirois
- Montreal Heart Institute Research Center, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada.,Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, 2900 Edouard-Montpetit Boulevard, Montreal, QC, H3T 1J4, Canada
| | - Louis Villeneuve
- Montreal Heart Institute Research Center, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
| | - Angelino Calderone
- Montreal Heart Institute Research Center, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada.,Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, 2900 Edouard-Montpetit Boulevard, Montreal, QC, H3T 1J4, Canada
| | - Alexandre Bergeron
- Montreal Heart Institute Research Center, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
| | - Emmanuelle Brochiero
- Department of Medicine, Faculty of Medicine, Université de Montréal, 2900 Edouard-Montpetit Boulevard, Montreal, QC, H3T 1J4, Canada.,Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 Saint-Denis Street, Montreal, QC, H2X 0A9, Canada
| | - Jean-Claude Tardif
- Montreal Heart Institute Research Center, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada.,Department of Medicine, Faculty of Medicine, Université de Montréal, 2900 Edouard-Montpetit Boulevard, Montreal, QC, H3T 1J4, Canada
| | - YanFen Shi
- Montreal Heart Institute Research Center, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada
| | - Jocelyn Dupuis
- Montreal Heart Institute Research Center, 5000 Belanger Street, Montreal, QC, H1T 1C8, Canada. .,Department of Medicine, Faculty of Medicine, Université de Montréal, 2900 Edouard-Montpetit Boulevard, Montreal, QC, H3T 1J4, Canada.
| |
Collapse
|
12
|
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Gouill S, Oberic L, Robak T, Jain P, Calvo R, Tao L, Dlugosz‐Danecka M. ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.58_2880] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Wang
- MD Anderson Cancer Center, University of Texas Lymphoma ‐ Myeloma, Division of Cancer Medicine Houston Texas USA
| | - S. Rule
- Plymouth University Medical School Hematology Plymouth UK
| | - P. L. Zinzani
- Institute of Hematology “Seràgnoli” University of Bologna Experimental, Diagnostic and Specialty Medicine ‐ DIMES Bologna Italy
| | - A. Goy
- John Theurer Cancer Center, Hackensack University Medical Center Oncology Hackensack New Jersey USA
| | - O. Casasnovas
- CHU Dijon ‐ Hôpital d’Enfants Hematology Dijon France
| | - S. D. Smith
- Fred Hutchinson Cancer Research Center, University of Washington Medical Oncology Seattle Washington USA
| | - G. Damaj
- Institut d’Hématologie de Basse‐Normandie Hematology Caen France
| | - J. K. Doorduijn
- Erasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium Hematology Rotterdam Netherlands
| | - T. Lamy
- CHU de Rennes Hematology Rennes France
| | - F. Morschhauser
- CHU Lille, ULR 7365 ‐ GRITA ‐ Groupe de Recherche sur les formes Injectables et les Technologies Associées Hematology Lille France
| | - C. Panizo
- Clínica Universidad de Navarra Hematology Pamplona Spain
| | - B. Shah
- Moffitt Cancer Center Malignant Hematology Tampa Florida USA
| | - A. Davies
- Cancer Research UK Experimental Cancer Medicines Centre, University of Southampton Faculty of Medicine Medical Oncology Southampton UK
| | - R. Eek
- Border Medical Oncology Medical Oncology Albury Australia
| | - J. Dupuis
- Unité Hémopathies Lymphoïdes AP‐HP Hôpital Henri Mondor, Hematology Créteil France
| | - E. Jacobsen
- Dana Farber Cancer Institute Harvard Medical School, Medical Oncology Boston Massachusetts USA
| | - A. P. Kater
- Amsterdam University Medical Center Amsterdam, on behalf of Hovon, Hematology, Lymphoma and Myeloma Research Amsterdam Netherlands
| | - S. Gouill
- CHU de Nantes—Hotel Dieu Hematology Nantes France
| | - L. Oberic
- Institut Universitaire du Cancer—Oncopole Toulouse (IUCT‐O) Hematology Toulouse France
| | - T. Robak
- Copernicus Memorial Hospital, Medical University of Lodz Hematology Lodz Poland
| | - P. Jain
- MD Anderson Cancer Center, University of Texas Leukemia Houston Texas USA
| | - R. Calvo
- AstraZeneca, Clinical Development Hematology R&D Oncology Gaithersburg Maryland USA
| | - L. Tao
- AstraZeneca Biostatistics South San Francisco California USA
| | - M. Dlugosz‐Danecka
- Maria Sklodowska‐Curie National Research Institute of Oncology Hematology Krakow Poland
| |
Collapse
|
13
|
Tardif JC, Bouabdallaoui N, L'Allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, da Luz P, Verret L, Audet S, Dupuis J, Denault A, Pelletier M, Tessier PA, Samson S, Fortin D, Tardif JD, Busseuil D, Goulet E, Lacoste C, Dubois A, Joshi AY, Waters DD, Hsue P, Lepor NE, Lesage F, Sainturet N, Roy-Clavel E, Bassevitch Z, Orfanos A, Stamatescu G, Grégoire JC, Busque L, Lavallée C, Hétu PO, Paquette JS, Deftereos SG, Levesque S, Cossette M, Nozza A, Chabot-Blanchet M, Dubé MP, Guertin MC, Boivin G. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med 2021. [PMID: 34051877 DOI: 10.1101/2021.01.26.21250494] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Evidence suggests a role for excessive inflammation in COVID-19 complications. Colchicine is an oral anti-inflammatory medication beneficial in gout, pericarditis, and coronary disease. We aimed to investigate the effect of colchicine on the composite of COVID-19-related death or hospital admission. METHODS The present study is a phase 3, randomised, double-blind, adaptive, placebo-controlled, multicentre trial. The study was done in Brazil, Canada, Greece, South Africa, Spain, and the USA, and was led by the Montreal Heart Institute. Patients with COVID-19 diagnosed by PCR testing or clinical criteria who were not being treated in hospital were eligible if they were at least 40 years old and had at least one high-risk characteristic. The randomisation list was computer-generated by an unmasked biostatistician, and masked randomisation was centralised and done electronically through an automated interactive web-response system. The allocation sequence was unstratified and used a 1:1 ratio with a blocking schema and block sizes of six. Patients were randomly assigned to receive orally administered colchicine (0·5 mg twice per day for 3 days and then once per day for 27 days thereafter) or matching placebo. The primary efficacy endpoint was the composite of death or hospital admission for COVID-19. Vital status at the end of the study was available for 97·9% of patients. The analyses were done according to the intention-to-treat principle. The COLCORONA trial is registered with ClinicalTrials.gov (NCT04322682) and is now closed to new participants. FINDINGS Trial enrolment began in March 23, 2020, and was completed in Dec 22, 2020. A total of 4488 patients (53·9% women; median age 54·0 years, IQR 47·0-61·0) were enrolled and 2235 patients were randomly assigned to colchicine and 2253 to placebo. The primary endpoint occurred in 104 (4·7%) of 2235 patients in the colchicine group and 131 (5·8%) of 2253 patients in the placebo group (odds ratio [OR] 0·79, 95·1% CI 0·61-1·03; p=0·081). Among the 4159 patients with PCR-confirmed COVID-19, the primary endpoint occurred in 96 (4·6%) of 2075 patients in the colchicine group and 126 (6·0%) of 2084 patients in the placebo group (OR 0·75, 0·57-0·99; p=0·042). Serious adverse events were reported in 108 (4·9%) of 2195 patients in the colchicine group and 139 (6·3%) of 2217 patients in the placebo group (p=0·051); pneumonia occurred in 63 (2·9%) of 2195 patients in the colchicine group and 92 (4·1%) of 2217 patients in the placebo group (p=0·021). Diarrhoea was reported in 300 (13·7%) of 2195 patients in the colchicine group and 161 (7·3%) of 2217 patients in the placebo group (p<0·0001). INTERPRETATION In community-treated patients including those without a mandatory diagnostic test, the effect of colchicine on COVID-19-related clinical events was not statistically significant. Among patients with PCR-confirmed COVID-19, colchicine led to a lower rate of the composite of death or hospital admission than placebo. Given the absence of orally administered therapies to prevent COVID-19 complications in community-treated patients and the benefit of colchicine in patients with PCR-proven COVID-19, this safe and inexpensive anti-inflammatory agent could be considered for use in those at risk of complications. Notwithstanding these considerations, replication in other studies of PCR-positive community-treated patients is recommended. FUNDING The Government of Quebec, the Bill & Melinda Gates Foundation, the National Heart, Lung, and Blood Institute of the US National Institutes of Health, the Montreal Heart Institute Foundation, the NYU Grossman School of Medicine, the Rudin Family Foundation, and philanthropist Sophie Desmarais.
Collapse
Affiliation(s)
| | | | | | - Daniel Gaudet
- Ecogene-21, Université de Montréal, Montreal, QC, Canada; Department of Medicine, Université de Montréal, Montreal, QC, Canada
| | - Binita Shah
- New York University Grossman School of Medicine, New York, NY, USA
| | | | | | - Protasio da Luz
- Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil
| | - Lucie Verret
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Sylvia Audet
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Jocelyn Dupuis
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - André Denault
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Martin Pelletier
- Centre Hospitalier Universitaire de Québec, Université Laval, Quebec City, QC, Canada
| | - Philippe A Tessier
- Centre Hospitalier Universitaire de Québec, Université Laval, Quebec City, QC, Canada
| | - Sarah Samson
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Denis Fortin
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | | | - David Busseuil
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Elisabeth Goulet
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Chantal Lacoste
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Anick Dubois
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | | | | | | | - Norman E Lepor
- Cedars-Sinai Heart Institute, Geffen School of Medicine-UCLA, Los Angeles, CA, USA
| | - Frédéric Lesage
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Nicolas Sainturet
- Montréal Health Innovations Coordinating Center, Montreal, QC, Canada
| | - Eve Roy-Clavel
- Montréal Health Innovations Coordinating Center, Montreal, QC, Canada
| | - Zohar Bassevitch
- Montréal Health Innovations Coordinating Center, Montreal, QC, Canada
| | - Andreas Orfanos
- Montréal Health Innovations Coordinating Center, Montreal, QC, Canada
| | | | - Jean C Grégoire
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Lambert Busque
- Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada
| | - Christian Lavallée
- Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada
| | | | | | - Spyridon G Deftereos
- Second Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece
| | - Sylvie Levesque
- Montréal Health Innovations Coordinating Center, Montreal, QC, Canada
| | - Mariève Cossette
- Montréal Health Innovations Coordinating Center, Montreal, QC, Canada
| | - Anna Nozza
- Montréal Health Innovations Coordinating Center, Montreal, QC, Canada
| | | | - Marie-Pierre Dubé
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | | | - Guy Boivin
- Centre Hospitalier Universitaire de Québec, Université Laval, Quebec City, QC, Canada
| | | |
Collapse
|
14
|
Zhu L, Liu F, Hao Q, Feng T, Chen Z, Luo S, Xiao R, Sun M, Zhang T, Fan X, Zeng X, He J, Yuan P, Liu J, Ruiz M, Dupuis J, Hu Q. Dietary Geranylgeranyl Pyrophosphate Counteracts the Benefits of Statin Therapy in Experimental Pulmonary Hypertension. Circulation 2021; 143:1775-1792. [PMID: 33660517 DOI: 10.1161/circulationaha.120.046542] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND The mevalonate pathway generates endogenous cholesterol and intermediates including geranylgeranyl pyrophosphate (GGPP). By reducing GGPP production, statins exert pleiotropic or cholesterol-independent effects. The potential regulation of GGPP homeostasis through dietary intake and the interaction with concomitant statin therapy is unknown. METHODS We developed a sensitive high-pressure liquid chromatography technique to quantify dietary GGPP and conducted proteomics, qualitative real-time polymerase chain reaction screening, and Western blot to determine signaling cascades, gene expression, protein-protein interaction, and protein membrane trafficking in wild-type and transgenic rats. RESULTS GGPP contents were highly variable depending on food source that differentially regulated blood GGPP levels in rats. Diets containing intermediate and high GGPP reduced or abolished the effects of statins in rats with hypoxia- and monocrotaline-induced pulmonary hypertension: this was rescuable by methyl-allylthiosulfinate and methyl-allylthiosulfinate-rich garlic extracts. In human pulmonary artery smooth muscle cells treated with statins, hypoxia activated RhoA in an extracellular GGPP-dependent manner. Hypoxia-induced ROCK2 (Rho associated coiled-coil containing protein kinase 2)/Rab10 (Ras-related protein rab-10) signaling was prevented by statin and recovered by exogenous GGPP. The hypoxia-activated RhoA/ROCK2 pathway in rat and human pulmonary artery smooth muscle cells upregulated the expression of Ca2+-sensing receptor (CaSR) and HIMF (hypoxia-induced mitogenic factor), a mechanism attenuated by statin treatment and regained with exogenous GGPP. Rab10 knockdown almost abrogated hypoxia-promoted CaSR membrane trafficking, a process diminished by statin and resumed by exogenous GGPP. Hypoxia-induced pulmonary hypertension was reduced in rats with CaSR mutated at the binding motif of HIMF and the interaction between dietary GGPP and statin efficiency was abolished. In humans fed a high GGPP diet, blood GGPP levels were increased. This abolished statin-lowering effects on plasma GGPP, and also on hypoxia-enhanced RhoA activity of blood monocytes that was rescued by garlic extracts. CONCLUSIONS There is important dietary regulation of GGPP levels that interferes with the effects of statin therapy in experimental pulmonary hypertension. These observations rely on a key and central role of RhoA-ROCK2 cascade activation and Rab10-faciliated CaSR membrane trafficking with subsequent overexpression and binding of HIMF to CaSR. These findings warrant clinical investigation for the treatment of pulmonary hypertension and perhaps other diseases by combining statin with garlic-derived methyl-allylthiosulfinate or garlic extracts and thus circumventing dietary GGPP variations.
Collapse
Affiliation(s)
- Liping Zhu
- Department of Pathophysiology, School of Basic Medicine (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Fangbo Liu
- Department of Pathophysiology, School of Basic Medicine (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Qiang Hao
- Department of Pathophysiology, School of Basic Medicine (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Tian Feng
- Department of Pathophysiology, School of Basic Medicine (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Zeshuai Chen
- Department of Pathophysiology, School of Basic Medicine (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Shengquan Luo
- Department of Pathophysiology, School of Basic Medicine (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Rui Xiao
- Department of Pathophysiology, School of Basic Medicine (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Mengxiang Sun
- Department of Pathophysiology, School of Basic Medicine (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Ting Zhang
- Department of Pathophysiology, School of Basic Medicine (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Xiaohang Fan
- Department of Pathophysiology, School of Basic Medicine (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Xianqin Zeng
- Department of Pathophysiology, School of Basic Medicine (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jianguo He
- State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (J.H.)
| | - Ping Yuan
- Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China (P.Y., J.L.)
| | - Jinming Liu
- Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China (P.Y., J.L.)
| | - Matthieu Ruiz
- Departments of Nutrition (M.R.), Université de Montréal, Canada.,Montreal Heart Institute Research Center, Canada (M.R., J.D.)
| | - Jocelyn Dupuis
- Medicine (J.D.), Université de Montréal, Canada.,Montreal Heart Institute Research Center, Canada (M.R., J.D.)
| | - Qinghua Hu
- Department of Pathophysiology, School of Basic Medicine (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., F.L., Q. Hao, T.F., Z.C., S.L., R.X., M.S., T.Z., X.F., X.Z., Q. Hu), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
15
|
Dupuis J, Sirois MG, Rhéaume E, Nguyen QT, Clavet-Lanthier MÉ, Brand G, Mihalache-Avram T, Théberge-Julien G, Charpentier D, Rhainds D, Neagoe PE, Tardif JC. Colchicine reduces lung injury in experimental acute respiratory distress syndrome. PLoS One 2020; 15:e0242318. [PMID: 33264297 PMCID: PMC7710059 DOI: 10.1371/journal.pone.0242318] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 10/30/2020] [Indexed: 12/28/2022] Open
Abstract
The acute respiratory distress syndrome (ARDS) is characterized by intense dysregulated inflammation leading to acute lung injury (ALI) and respiratory failure. There are no effective pharmacologic therapies for ARDS. Colchicine is a low-cost, widely available drug, effective in the treatment of inflammatory conditions. We studied the effects of colchicine pre-treatment on oleic acid-induced ARDS in rats. Rats were treated with colchicine (1 mg/kg) or placebo for three days prior to intravenous oleic acid-induced ALI (150 mg/kg). Four hours later they were studied and compared to a sham group. Colchicine reduced the area of histological lung injury by 61%, reduced lung edema, and markedly improved oxygenation by increasing PaO2/FiO2 from 66 ± 13 mmHg (mean ± SEM) to 246 ± 45 mmHg compared to 380 ± 18 mmHg in sham animals. Colchicine also reduced PaCO2 and respiratory acidosis. Lung neutrophil recruitment, assessed by myeloperoxidase immunostaining, was greatly increased after injury from 1.16 ± 0.19% to 8.86 ± 0.66% and significantly reduced by colchicine to 5.95 ± 1.13%. Increased lung NETosis was also reduced by therapy. Circulating leukocytosis after ALI was not reduced by colchicine therapy, but neutrophils reactivity and CD4 and CD8 cell surface expression on lymphocyte populations were restored. Colchicine reduces ALI and respiratory failure in experimental ARDS in relation with reduced lung neutrophil recruitment and reduced circulating leukocyte activation. This study supports the clinical development of colchicine for the prevention of ARDS in conditions causing ALI.
Collapse
Affiliation(s)
- Jocelyn Dupuis
- Montreal Heart Institute Research Center, Montreal, Quebec, Canada
- Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
| | - Martin G. Sirois
- Montreal Heart Institute Research Center, Montreal, Quebec, Canada
- Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
| | - Eric Rhéaume
- Montreal Heart Institute Research Center, Montreal, Quebec, Canada
- Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
| | - Quang T. Nguyen
- Montreal Heart Institute Research Center, Montreal, Quebec, Canada
| | | | - Genevieve Brand
- Montreal Heart Institute Research Center, Montreal, Quebec, Canada
| | | | | | | | - David Rhainds
- Montreal Heart Institute Research Center, Montreal, Quebec, Canada
| | | | - Jean-Claude Tardif
- Montreal Heart Institute Research Center, Montreal, Quebec, Canada
- Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
| |
Collapse
|
16
|
Tan R, Li J, Liu F, Liao P, Ruiz M, Dupuis J, Zhu L, Hu Q. Phenylalanine induces pulmonary hypertension through calcium-sensing receptor activation. Am J Physiol Lung Cell Mol Physiol 2020; 319:L1010-L1020. [PMID: 32964725 DOI: 10.1152/ajplung.00215.2020] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Phenylalanine levels are associated with pulmonary hypertension in metabolic profiling clinical studies. However, the pathophysiological role of phenylalanine on pulmonary circulation is still unclear. We experimentally addressed the direct impact of phenylalanine on pulmonary circulation in rats and explored the underlying molecular pathway. Phenylalanine was injected intraperitoneally into Sprague-Dawley rats (400 mg/100 g body wt) as a single dose or daily in a chronic manner for 2, 3, and 4 wk. Chronic injection of phenylalanine induced pulmonary hypertension with time-dependent severity, evidenced by elevated pulmonary artery pressure and pulmonary vascular resistance as well as pulmonary artery and right ventricular hypertrophy. Using tandem mass spectrometry analysis, we found a quick twofold increase in blood level of phenylalanine 2 h following injection. This increase led to a significant accumulation of phenylalanine in lung after 4 h, which remained sustained at up to a threefold increase after 4 wk. In addition, a cellular thermal shift assay with lung tissues from phenylalanine-injected rats revealed the binding of phenylalanine to the calcium-sensing receptor (CaSR). In vitro experiments with cultured pulmonary arterial smooth muscle cells showed that phenylalanine activated CaSR, as indicated by an increase in intracellular calcium content, which was attenuated or diminished by the inhibition or knockdown of CaSR. Finally, the global knockout or lung-specific knockdown of CaSR significantly attenuated phenylalanine-induced pulmonary hypertension. Chronic phenylalanine injection induces pulmonary hypertension through binding to CaSR and its subsequent activation. Here, we demonstrate a pathophysiological role of phenylalanine in pulmonary hypertension through the CaSR. This study provides a novel animal model for pulmonary hypertension and reveals a potentially clinically significant role for this metabolite in human pulmonary hypertension as a marker, a mediator of disease, and a possible therapeutic target.
Collapse
Affiliation(s)
- Rubin Tan
- Department of Pathophysiology, School of Basic Medicine; and Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Physiology, School of Basic Medicine, Xuzhou Medical University, Xuzhou, China
| | - Jiansha Li
- Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Fangbo Liu
- Department of Pathophysiology, School of Basic Medicine; and Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Pu Liao
- Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Matthieu Ruiz
- Department of Medicine, Université de Montréal, Montreal, Quebec, Canada.,Montreal Heart Institute Research Center, Montreal, Quebec, Canada
| | - Jocelyn Dupuis
- Department of Medicine, Université de Montréal, Montreal, Quebec, Canada.,Montreal Heart Institute Research Center, Montreal, Quebec, Canada
| | - Liping Zhu
- Department of Pathophysiology, School of Basic Medicine; and Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Qinghua Hu
- Department of Pathophysiology, School of Basic Medicine; and Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
17
|
Nguyen QT, Nsaibia MJ, Sirois MG, Calderone A, Tardif JC, Fen Shi Y, Ruiz M, Daneault C, Gagnon L, Grouix B, Laurin P, Dupuis J. PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure. Cardiovasc Res 2020; 116:171-182. [PMID: 30753422 DOI: 10.1093/cvr/cvz034] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2018] [Revised: 01/15/2019] [Accepted: 02/06/2019] [Indexed: 11/14/2022] Open
Abstract
AIMS Heart failure with reduced ejection fraction (HFrEF) causes lung remodelling with myofibroblasts proliferation and fibrosis leading to a restrictive lung syndrome with pulmonary hypertension (PH) and right ventricular (RV) dysfunction. PBI-4050 is a first-in-class anti-fibrotic, anti-inflammatory, and anti-proliferative compound. The present study evaluated the therapeutic impact of PBI-4050 on PH in an HFrEF model. METHODS AND RESULTS HFrEF was induced after myocardial infarction (MI) in rats. Two weeks later, sham-operated and MI groups received PBI-4050 (200 mg/kg/day by gavage) or saline for 3 weeks. Animals were analysed according to infarct size as large (≥30% left ventricle) or medium MI (<30%). Large MI caused PH and RV hypertrophy (RVH) with a restrictive lung syndrome. PBI-4050 did not adversely affect left ventricular (LV) function but markedly reduced PH and RVH and improved RV dysfunction. PBI-4050 reduced lung remodelling and improved respiratory compliance with decreased lung fibrosis, alveolar wall cellular proliferation and α-smooth muscle actin expression. The increased expression of endothelin-1 (ET-1), transforming growth factor beta (TGF-β), interleukin-6 (IL-6) and of tissue inhibitor of metalloprotease-1 in the lungs from HFrEF were reduced with PBI-4050 therapy. Activation of isolated human lung fibroblasts (HLFs) to a myofibroblastic pro-fibrogenic phenotype was markedly reduced by PBI-4050. The fatty acid receptor GPR84 was increased in HFrEF lungs and in activated HLFs, and reduced by PBI-4050. GPR84 agonists activated fibrogenesis in HLFs and finally, PBI-4050 reduced ERK1/2 phosphorylation. CONCLUSIONS PBI-4050 reduces PH and RVH in HFrEF by decreasing lung fibrosis and remodelling. This novel agent decreases the associated restrictive lung syndrome and recovers RV function. A contributing mechanism involves reducing the activation of lung fibroblasts by IL-6, TGF-β, and ET-1 by antagonism of GPR84 and reduced ERK1/2 phosphorylation. PBI-4050 is a novel promising therapy for targeting lung remodelling in group II PH.
Collapse
Affiliation(s)
- Quang T Nguyen
- Research Center, Montreal Heart Institute, 5000 Bélanger est, Montreal, QC H1T 1C8, Canada
| | - Mohamed J Nsaibia
- Research Center, Montreal Heart Institute, 5000 Bélanger est, Montreal, QC H1T 1C8, Canada.,Prometic Biosciences Inc., 440 Boulevard Armand-Frappier, QC, H7V 4B4, Canada
| | - Martin G Sirois
- Research Center, Montreal Heart Institute, 5000 Bélanger est, Montreal, QC H1T 1C8, Canada.,Département de Pharmacologie et Physiologie et Département de Médecine, Faculté de Médecine, Université de Montréal, 2900 Boulevard Édouard-Montpetit, Montréal, QC, H3T 1J4, Canada
| | - Angelino Calderone
- Research Center, Montreal Heart Institute, 5000 Bélanger est, Montreal, QC H1T 1C8, Canada.,Département de Pharmacologie et Physiologie et Département de Médecine, Faculté de Médecine, Université de Montréal, 2900 Boulevard Édouard-Montpetit, Montréal, QC, H3T 1J4, Canada
| | - Jean-Claude Tardif
- Research Center, Montreal Heart Institute, 5000 Bélanger est, Montreal, QC H1T 1C8, Canada.,Département de Pharmacologie et Physiologie et Département de Médecine, Faculté de Médecine, Université de Montréal, 2900 Boulevard Édouard-Montpetit, Montréal, QC, H3T 1J4, Canada
| | - Yan Fen Shi
- Research Center, Montreal Heart Institute, 5000 Bélanger est, Montreal, QC H1T 1C8, Canada
| | - Matthieu Ruiz
- Research Center, Montreal Heart Institute, 5000 Bélanger est, Montreal, QC H1T 1C8, Canada.,Département de Pharmacologie et Physiologie et Département de Médecine, Faculté de Médecine, Université de Montréal, 2900 Boulevard Édouard-Montpetit, Montréal, QC, H3T 1J4, Canada
| | - Caroline Daneault
- Research Center, Montreal Heart Institute, 5000 Bélanger est, Montreal, QC H1T 1C8, Canada
| | - Lyne Gagnon
- Prometic Biosciences Inc., 440 Boulevard Armand-Frappier, QC, H7V 4B4, Canada
| | - Brigitte Grouix
- Prometic Biosciences Inc., 440 Boulevard Armand-Frappier, QC, H7V 4B4, Canada
| | - Pierre Laurin
- Prometic Biosciences Inc., 440 Boulevard Armand-Frappier, QC, H7V 4B4, Canada
| | - Jocelyn Dupuis
- Research Center, Montreal Heart Institute, 5000 Bélanger est, Montreal, QC H1T 1C8, Canada.,Département de Pharmacologie et Physiologie et Département de Médecine, Faculté de Médecine, Université de Montréal, 2900 Boulevard Édouard-Montpetit, Montréal, QC, H3T 1J4, Canada
| |
Collapse
|
18
|
Mury P, Dupuis J, Thorin E. A Novel Molecular Pathway of Plaque Vulnerability Reveals a Cholesterol-Independent Effect of Statins and Supports Inflammation as a Therapeutic Target. Can J Cardiol 2020; 36:1710-1713. [PMID: 32315602 DOI: 10.1016/j.cjca.2020.02.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 02/06/2020] [Accepted: 02/06/2020] [Indexed: 11/29/2022] Open
Affiliation(s)
- Pauline Mury
- Faculty of Medicine, Department of Pharmacology and Physiology, University of Montreal, Montreal, Québec, Canada; Montreal Heart Institute, Research Center, Montreal, Québec, Canada.
| | - Jocelyn Dupuis
- Montreal Heart Institute, Research Center, Montreal, Québec, Canada; Faculty of Medicine, Department of Medicine, University of Montreal, Montreal, Québec, Canada
| | - Eric Thorin
- Faculty of Medicine, Department of Pharmacology and Physiology, University of Montreal, Montreal, Québec, Canada; Montreal Heart Institute, Research Center, Montreal, Québec, Canada; Faculty of Medicine, Department of Surgery, University of Montreal, Montreal, Québec, Canada
| |
Collapse
|
19
|
Legris V, Thibault B, Dupuis J, White M, Fortier A, Henri C, O'Meara E, Ducharme A. Right Ventricular Function Coupling to the Pulmonary Circulation Predicts Exercise Tolerance in Patients with Heart Failure and Reduced Ejection Fraction. Insight from the Evaluation of Resynchronization Therapy for Heart Failure (EARTH) Trial. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
20
|
Legris V, Thibault B, Dupuis J, White M, Fortier A, Henri C, O'Meara E, Ducharme A. RIGHT VENTRICULAR FUNCTION COUPLING TO THE PULMONARY CIRCULATION PREDICTS EXERCISE TOLERANCE IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHT FROM THE EVALUATION OF RESYNCHRONIZATION THERAPY FOR HEART FAILURE (EARTH) TRIAL. J Am Coll Cardiol 2020. [DOI: 10.1016/s0735-1097(20)31452-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
21
|
Zhu L, Xiao R, Zhang X, Lang Y, Liu F, Yu Z, Zhang J, Su Y, Lu Y, Wang T, Luo S, Wang J, Liu ML, Dupuis J, Jing ZC, Li T, Xiong W, Hu Q. Spermine on Endothelial Extracellular Vesicles Mediates Smoking-Induced Pulmonary Hypertension Partially Through Calcium-Sensing Receptor. Arterioscler Thromb Vasc Biol 2020; 39:482-495. [PMID: 30626206 DOI: 10.1161/atvbaha.118.312280] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Objective- This study aims to determine whether and how the enriched metabolites of endothelial extracellular vesicles (eEVs) are critical for cigarette smoke-induced direct injury of endothelial cells and the development of pulmonary hypertension, rarely explored in contrast to long-investigated mechanisms secondary to chronic hypoxemia. Approach and Results- Metabonomic screen of eEVs from cigarette-smoking human subjects reveals prominent elevation of spermine-a polyamine metabolite with potent agonist activity for the extracellular CaSR (calcium-sensing receptor). CaSR inhibition with the negative allosteric modulator Calhex231 or CaSR knockdown attenuates cigarette smoke-induced pulmonary hypertension in rats without emphysematous changes in lungs or chronic hypoxemia. Cigarette smoke exposure increases the generation of spermine-positive eEVs and their spermine content. Immunocytochemical staining and immunogold electron microscopy recognize the spermine enrichment not only within the cytosol but also on the outer surface of eEV membrane. The repression of spermine synthesis, the inhibitory analog of spermine, N1-dansyl-spermine, Calhex231, or CaSR knockdown profoundly suppresses eEV exposure-mobilized cytosolic calcium signaling, pulmonary artery constriction, and smooth muscle cell proliferation. Confocal imaging of immunohistochemical staining demonstrates the migration of spermine-positive eEVs from endothelium into smooth muscle cells in pulmonary arteries of cigarette smoke-exposed rats. The repression of spermine synthesis or CaSR knockout results in attenuated development of pulmonary hypertension induced by an intravascular administration of eEVs. Conclusions- Cigarette smoke enhances eEV generation with spermine enrichment at their outer surface and cytosol, which activates CaSR and subsequently causes smooth muscle cell constriction and proliferation, therefore, directly leading to the development of pulmonary hypertension.
Collapse
Affiliation(s)
- Liping Zhu
- From the Department of Pathophysiology, School of Basic Medicine (L.Z., R.X., X.Z., Y.L., F.L., Z.Y., S.L., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.)
| | - Rui Xiao
- From the Department of Pathophysiology, School of Basic Medicine (L.Z., R.X., X.Z., Y.L., F.L., Z.Y., S.L., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.)
| | - Xiuyun Zhang
- From the Department of Pathophysiology, School of Basic Medicine (L.Z., R.X., X.Z., Y.L., F.L., Z.Y., S.L., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.)
| | - Yuheng Lang
- Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.).,Department of Pathology and Department of Respiratory and Critical Care Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (Y.L., T.W., W.X.)
| | - Fangbo Liu
- From the Department of Pathophysiology, School of Basic Medicine (L.Z., R.X., X.Z., Y.L., F.L., Z.Y., S.L., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.)
| | - Zhe Yu
- From the Department of Pathophysiology, School of Basic Medicine (L.Z., R.X., X.Z., Y.L., F.L., Z.Y., S.L., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.)
| | - Jiwei Zhang
- Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.).,Department of Pathology and Department of Respiratory and Critical Care Medicine, Union Hospital (J.Z., Y.S.)
| | - Yuan Su
- Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.).,Department of Pathology and Department of Respiratory and Critical Care Medicine, Union Hospital (J.Z., Y.S.)
| | - Yankai Lu
- From the Department of Pathophysiology, School of Basic Medicine (L.Z., R.X., X.Z., Y.L., F.L., Z.Y., S.L., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.)
| | - Tao Wang
- Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.).,Department of Pathology and Department of Respiratory and Critical Care Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (Y.L., T.W., W.X.)
| | - Shengquan Luo
- From the Department of Pathophysiology, School of Basic Medicine (L.Z., R.X., X.Z., Y.L., F.L., Z.Y., S.L., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.)
| | - Jian Wang
- State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China (J.W.)
| | - Ming-Lin Liu
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (M.-L.L.).,Philadelphia Veterans Administration Medical Center (M.-L.L.)
| | - Jocelyn Dupuis
- Montreal Heart Institute, Québec, Canada (J.D.).,Department of medicine, Université de Montréal, Québec, Canada (J.D.)
| | - Zhi-Cheng Jing
- State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (Z.-C.J.)
| | - Tong Li
- Department of Heart Centre and Artificial Cell Engineering Technology Research Center of Public Health Ministry, Third Central Clinical College, Tianjin Medical University, China (T.L.)
| | - Weining Xiong
- Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.).,Department of Pathology and Department of Respiratory and Critical Care Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (Y.L., T.W., W.X.)
| | - Qinghua Hu
- From the Department of Pathophysiology, School of Basic Medicine (L.Z., R.X., X.Z., Y.L., F.L., Z.Y., S.L., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (L.Z., R.X., X.Z., Y.Lang, F.L., Z.Y., J.Z., Y.S., Y.Lu, T.W., S.L., W.X., Q.H.)
| |
Collapse
|
22
|
Alonso Martinez LM, Harel F, Létourneau M, Finnerty V, Fournier A, Dupuis J, DaSilva JN. SPECT and PET imaging of adrenomedullin receptors: a promising strategy for studying pulmonary vascular diseases. Am J Nucl Med Mol Imaging 2019; 9:203-215. [PMID: 31772819 PMCID: PMC6872478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Accepted: 09/10/2019] [Indexed: 06/10/2023]
Abstract
Circulating adrenomedullin (AM) levels are elevated in several cardiovascular diseases, including pulmonary vascular diseases causing pulmonary hypertension. To date the perfusion agent 99mTc-albumin macroaggregates (MAA) is the only approved radiopharmaceutical used for imaging of pulmonary circulation. Unlike 99mTc-MAA, imaging the AM receptors involves a molecular process dependent on the density of the receptors and the affinity of specific radioligands. The AM receptors are abundantly distributed in lung capillaries and its integrity provides protection in the development of pulmonary vascular diseases. This review summarizes the development and characterization of radioligands for in vivo imaging of AM receptors as an early predictor of the onset of a pulmonary vascular disease.
Collapse
Affiliation(s)
- Luis Michel Alonso Martinez
- University of Montreal Hospital Research CentreMontréal (Québec), Canada
- Department of Biomedical Engineering, Faculty of Medicine, Université de MontréalMontréal (Québec), Canada
- Research Center of The Montreal Heart InstituteMontréal (Québec), Canada
| | - François Harel
- Department of Biomedical Engineering, Faculty of Medicine, Université de MontréalMontréal (Québec), Canada
- Research Center of The Montreal Heart InstituteMontréal (Québec), Canada
- Department of Radiology, Radio-Oncology and Nuclear Medicine, Université de MontréalMontréal (Québec), Canada
| | - Myriam Létourneau
- Laboratoire D’Études Moléculaires Et Pharmacologiques Des Peptides, INRS-Centre Armand-Frappier Santé BiotechnologieLaval (Québec), Canada
| | - Vincent Finnerty
- Research Center of The Montreal Heart InstituteMontréal (Québec), Canada
| | - Alain Fournier
- Laboratoire D’Études Moléculaires Et Pharmacologiques Des Peptides, INRS-Centre Armand-Frappier Santé BiotechnologieLaval (Québec), Canada
| | - Jocelyn Dupuis
- Research Center of The Montreal Heart InstituteMontréal (Québec), Canada
- Department of Medicine, Université de MontréalMontréal (Québec), Canada
| | - Jean N DaSilva
- University of Montreal Hospital Research CentreMontréal (Québec), Canada
- Department of Biomedical Engineering, Faculty of Medicine, Université de MontréalMontréal (Québec), Canada
- Department of Radiology, Radio-Oncology and Nuclear Medicine, Université de MontréalMontréal (Québec), Canada
| |
Collapse
|
23
|
Ruiz M, Tremblay-Gravel M, Ruiz M, Fortier A, Ducharme A, Tardif J, Rosiers CD, Dupuis J. METABOLOMICS ANALYSIS DISCRIMINATES HEART FAILURE PATIENTS ACCORDING TO PULMONARY HYPERTENSION: A PROOF-OF-PRINCIPLE STUDY. Can J Cardiol 2019. [DOI: 10.1016/j.cjca.2019.07.588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
24
|
Kayser JW, Cossette S, Côté J, Tanguay JF, Tremblay JF, Diodati JG, Bourbonnais A, Purden M, Juneau M, Terrier J, Dupuis J, Maheu-Cadotte MA, Fontaine G, Cournoyer D. A web-based tailored nursing intervention (TAVIE en m@rche) aimed at increasing walking after an acute coronary syndrome: Multicentre randomized trial. J Adv Nurs 2019; 75:2727-2741. [PMID: 31225667 DOI: 10.1111/jan.14119] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Revised: 04/13/2019] [Accepted: 04/17/2019] [Indexed: 11/26/2022]
Abstract
AIM Evaluate a web-based tailored nursing intervention, TAVIE en m@rche, on increasing daily steps after an acute coronary syndrome. DESIGN Parallel two-group multicentre randomized trial. METHODS An experimental group receiving TAVIE en m@rche, was compared to a control group receiving hyperlinks to public websites. Acute coronary syndrome patients who were insufficiently active were recruited from three coronary care units. Daily steps at 12 weeks were the primary outcome. Secondary outcomes included self-reported walking and moderate to vigorous physical activity (MVPA). Exploratory outcomes were angina frequency, emergency department visits, hospitalizations and secondary prevention programme attendance. RESULTS Primary data were analysed for 39 participants. No significant effects were found. At 12 weeks 275.9 more daily steps and 1,464.3 more energy expenditure in MVPA were found in the experimental group relative to the control. No effects were found for angina frequency, emergency department visits, hospitalizations and secondary prevention programme attendance. CONCLUSION The lack of effect on our primary result may be explained by the intervention goal that was mismatched to the needs of our mostly sufficiently active sample at randomization, resulting in no meaningful change in daily steps. Although the non-significantly greater increase in self-reported MVPA may represent gains in health among the participants that accessed TAVIE en m@rche, this result should be interpreted with caution. IMPACT From 40%-60% of acute coronary syndrome patients self-report insufficient levels of physical activity. No effect was found on the primary outcome of daily steps. Although not significant, a greater increase in MVPA was found at 12 weeks. The primary outcome can be explained by most of the sample having attained the physical activity recommendation at randomization. Caution in interpreting the non-significant increase in MVPA is warranted due to attrition bias and statistical uncertainty. Future directions may consider the timing of randomization in relation to meeting the needs of insufficiently active acute coronary syndrome patients.
Collapse
Affiliation(s)
- John William Kayser
- Faculty of Nursing, Université de Montréal, Montréal, Quebec, Canada.,Montreal Heart Institute Research Center, Department of Medicine, Université de Montréal, Montréal, Quebec, Canada
| | - Sylvie Cossette
- Faculty of Nursing, Université de Montréal, Montréal, Quebec, Canada.,Montreal Heart Institute Research Center, Department of Medicine, Université de Montréal, Montréal, Quebec, Canada
| | - José Côté
- Faculty of Nursing, Université de Montréal, Montréal, Quebec, Canada.,Research Center of the Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
| | - Jean-Francois Tanguay
- Montreal Heart Institute Research Center, Department of Medicine, Université de Montréal, Montréal, Quebec, Canada
| | - Jean-Francois Tremblay
- Integrated Health and Social Services Centres, l'Est de l'Île de Montréal, Montréal, Quebec, Canada
| | | | - Anne Bourbonnais
- Faculty of Nursing, Université de Montréal, Montréal, Quebec, Canada.,Research Center of the Institut universitaire de gériatrie de Montréal, Montréal, Quebec, Canada
| | - Margaret Purden
- Ingram School of Nursing, McGill University, Montréal, Quebec, Canada.,Jewish General Hospital Centre for Nursing Research, Montréal, Quebec, Canada
| | - Martin Juneau
- Montreal Heart Institute Research Center, Department of Medicine, Université de Montréal, Montréal, Quebec, Canada
| | - Julien Terrier
- Montreal Heart Institute Research Center, Department of Medicine, Université de Montréal, Montréal, Quebec, Canada
| | - Jocelyn Dupuis
- Montreal Heart Institute Research Center, Department of Medicine, Université de Montréal, Montréal, Quebec, Canada
| | - Marc-André Maheu-Cadotte
- Faculty of Nursing, Université de Montréal, Montréal, Quebec, Canada.,Montreal Heart Institute Research Center, Department of Medicine, Université de Montréal, Montréal, Quebec, Canada.,Research Center of the Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
| | - Guillaume Fontaine
- Faculty of Nursing, Université de Montréal, Montréal, Quebec, Canada.,Montreal Heart Institute Research Center, Department of Medicine, Université de Montréal, Montréal, Quebec, Canada
| | - Daniel Cournoyer
- Montreal Health Innovations Coordinating Center, Montréal, Quebec, Canada
| |
Collapse
|
25
|
Ranchoux B, Nadeau V, Bourgeois A, Provencher S, Tremblay É, Omura J, Coté N, Abu-Alhayja'a R, Dumais V, Nachbar RT, Tastet L, Dahou A, Breuils-Bonnet S, Marette A, Pibarot P, Dupuis J, Paulin R, Boucherat O, Archer SL, Bonnet S, Potus F. Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease. Circ Res 2019; 125:449-466. [PMID: 31154939 DOI: 10.1161/circresaha.118.314555] [Citation(s) in RCA: 67] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
RATIONALE Pulmonary hypertension (PH) due to left heart disease (LHD), or group 2 PH, is the most prevalent form of PH worldwide. PH due to LHD is often associated with metabolic syndrome (MetS). In 12% to 13% of cases, patients with PH due to LHD display vascular remodeling of pulmonary arteries (PAs) associated with poor prognosis. Unfortunately, the underlying mechanisms remain unknown; PH-targeted therapies for this group are nonexistent, and the development of a new preclinical model is crucial. Among the numerous pathways dysregulated in MetS, inflammation plays also a critical role in both PH and vascular remodeling. OBJECTIVE We hypothesized that MetS and inflammation may trigger the development of vascular remodeling in group 2 PH. METHODS AND RESULTS Using supracoronary aortic banding, we induced diastolic dysfunction in rats. Then we induced MetS by a combination of high-fat diet and olanzapine treatment. We used metformin treatment and anti-IL-6 (interleukin-6) antibodies to inhibit the IL-6 pathway. Compared with sham conditions, only supracoronary aortic banding+MetS rats developed precapillary PH, as measured by both echocardiography and right/left heart catheterization. PH in supracoronary aortic banding+MetS was associated with macrophage accumulation and increased IL-6 production in lung. PH was also associated with STAT3 (signal transducer and activator of transcription 3) activation and increased proliferation of PA smooth muscle cells, which contributes to remodeling of distal PA. We reported macrophage accumulation, increased IL-6 levels, and STAT3 activation in the lung of group 2 PH patients. In vitro, IL-6 activates STAT3 and induces human PA smooth muscle cell proliferation. Metformin treatment decreased inflammation, IL-6 levels, STAT3 activation, and human PA smooth muscle cell proliferation. In vivo, in the supracoronary aortic banding+MetS animals, reducing IL-6, either by anti-IL-6 antibody or metformin treatment, reversed pulmonary vascular remodeling and improve PH due to LHD. CONCLUSIONS We developed a new preclinical model of group 2 PH by combining MetS with LHD. We showed that MetS exacerbates group 2 PH. We provided evidence for the importance of the IL-6-STAT3 pathway in our experimental model of group 2 PH and human patients.
Collapse
Affiliation(s)
- Benoît Ranchoux
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Valérie Nadeau
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Alice Bourgeois
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Steeve Provencher
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Éve Tremblay
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Junichi Omura
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Nancy Coté
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Rami Abu-Alhayja'a
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Valérie Dumais
- Institut universitaire de cardiologie et de pneumologie de Québec Research Center, Laval University, Québec City, Canada (V.D., R.T.N., A.M.)
| | - Renato T Nachbar
- Institut universitaire de cardiologie et de pneumologie de Québec Research Center, Laval University, Québec City, Canada (V.D., R.T.N., A.M.)
| | - Lionel Tastet
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Abdellaziz Dahou
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Sandra Breuils-Bonnet
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - André Marette
- Institut universitaire de cardiologie et de pneumologie de Québec Research Center, Laval University, Québec City, Canada (V.D., R.T.N., A.M.)
| | - Philippe Pibarot
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Jocelyn Dupuis
- Institut de cardiologie de Montréal, Québec, Canada (J.D.)
| | - Roxane Paulin
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Olivier Boucherat
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - Stephen L Archer
- Department of Medicine, Queen's University, Kingston, Ontario, Canada (S.L.A., F.P.)
| | - Sébastien Bonnet
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.)
| | - François Potus
- From the Pulmonary Hypertension Research Group of the Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Laval University, Québec City, Canada (B.R., V.N., A.B., S.P., E.T., J.O., N.C., R.A-A., L.T., A.D., S.B.-B., P.P., R.P., O.B., S.B., F.P.).,Department of Medicine, Queen's University, Kingston, Ontario, Canada (S.L.A., F.P.)
| |
Collapse
|
26
|
Roulin L, Jais J, Poullot E, Robe C, Scherman E, Lemonnier F, Le Bras F, Maarek A, Belhadj K, Dupuis J, Hammoud M, El Gnaoui T, Mule S, Itti E, Delfau-Larue M, Gaulard P, Haioun C, Copie-Bergman C. CLINICAL, IMMUNOPHENOTYPIC AND GENETIC CHARACTERISTICS OF AGGRESSIVE (NON-BURKITT) B-CELL LYMPHOMA IN A REAL LIFE COHORT. Hematol Oncol 2019. [DOI: 10.1002/hon.13_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L. Roulin
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - J. Jais
- Biostatistics; Necker Hospital, APHP; Paris France
| | - E. Poullot
- Pathology Department; Henri Mondor Hospital, APHP; Créteil France
| | - C. Robe
- Pathology Department; Henri Mondor Hospital, APHP; Créteil France
| | | | - F. Lemonnier
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - F. Le Bras
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - A. Maarek
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - K. Belhadj
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - J. Dupuis
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - M. Hammoud
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - T. El Gnaoui
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - S. Mule
- Radiology Department; Henri Mondor Hospital, APHP; Créteil France
| | - E. Itti
- Nuclear Medicine Department; Henri Mondor Hospital, APHP; Créteil France
| | - M. Delfau-Larue
- Immunobiology and Haematology Department; Henri Mondor Hospital, APHP; Créteil France
| | - P. Gaulard
- Pathology Department; Henri Mondor Hospital, APHP; Créteil France
| | - C. Haioun
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - C. Copie-Bergman
- Pathology Department; Henri Mondor Hospital, APHP; Créteil France
| |
Collapse
|
27
|
Cazelles C, Belhadj K, Vellemans H, Camus V, Copi-Bergman C, Veresezan L, Itti E, Becker S, Carvalho M, Dupuis J, Fabien L, Lemonnier F, Roulin L, El Gnaoui T, Jardin F, Mounier N, Tilly H, Haioun C. RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN (R-GemOx) IN REFRACTORY/RELAPSED (R/R) DLBCL. A REAL LIFE STUDY IN PATIENTS INELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION. Hematol Oncol 2019. [DOI: 10.1002/hon.101_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - K. Belhadj
- Lymphoid Hemopathy; Henri Mondor; Créteil France
| | - H. Vellemans
- Department of Haematology; Universite de Rouen, Centre de Lutte anti Cancer H. Becquerel; Rouen France
| | - V. Camus
- Department of Haematology; Universite de Rouen, Centre de Lutte anti Cancer H. Becquerel; Rouen France
| | | | - L. Veresezan
- Pathology; Centre de Lutte anti Cancer H. Becquerel; Rouen France
| | - E. Itti
- Radiology; Henri Mondor; Créteil France
| | - S. Becker
- Radiology; Centre de Lutte anti Cancer H. Becquerel; Rouen France
| | | | - J. Dupuis
- Lymphoid Hemopathy; Henri Mondor; Créteil France
| | - L. Fabien
- Lymphoid Hemopathy; Henri Mondor; Créteil France
| | - F. Lemonnier
- Lymphoid Hemopathy; Henri Mondor; Créteil France
| | - L. Roulin
- Lymphoid Hemopathy; Henri Mondor; Créteil France
| | - T. El Gnaoui
- Lymphoid Hemopathy; Henri Mondor; Créteil France
| | - F. Jardin
- Department of Haematology; Universite de Rouen, Centre de Lutte anti Cancer H. Becquerel; Rouen France
| | - N. Mounier
- Hematology; L'Archet 2 Hospital; Nice France
| | - H. Tilly
- Department of Haematology; Universite de Rouen, Centre de Lutte anti Cancer H. Becquerel; Rouen France
| | - C. Haioun
- Lymphoid Hemopathy; Henri Mondor; Créteil France
| |
Collapse
|
28
|
Mollaret E, Gomez E, Nadel B, Naiglin L, Anquetin M, Barau C, Baseggio L, Bret C, Brisou G, Brousset P, Camara-Clayette V, Cartron G, Da Cunha K, Dartigues P, Dupuis J, Ghaleh B, Gravelle P, Houot R, Karmous-Gadacha O, Laurent C, Moreaux J, Pangault C, Ribrag V, Salles G, Szablewski V, Thouault V, Uze G, Verge V, Ysebaert L, Gaulard P, Fest T. CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, A CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD. Hematol Oncol 2019. [DOI: 10.1002/hon.38_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- E. Mollaret
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - E. Gomez
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - B. Nadel
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - L. Naiglin
- R&D; Carnot CALYM Institute; Pierre-Bénite France
| | - M. Anquetin
- Plateforme de Ressources Biologiques; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - C. Barau
- Plateforme de Ressources Biologiques; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - L. Baseggio
- Laboratoire d'Hématologie; Groupement Hospitalier Sud/Hospices Civils de Lyon; Pierre-Bénite France
| | - C. Bret
- Hématologie Biologique; CHU Montpellier; Montpellier France
| | - G. Brisou
- Hématologie Clinique; Groupement Hospitalier Sud/ Hospices Civils de Lyon; Pierre-Bénite France
| | - P. Brousset
- Pathology and Cytology Department; UMR1037 Centre de Recherche en Cancerologie de Toulouse, CHU Toulouse, IUCT Oncopole / Toulouse III Paul Sabatier University / Inserm; Toulouse France
| | - V. Camara-Clayette
- Laboratoire RT Hématologie (AMMICa INSERM US23/CNRS UMS3655); Gustave Roussy; Villejuif France
| | - G. Cartron
- Département d'Hématologie Clinique; CHU Montpellier; Montpellier France
| | - K. Da Cunha
- CRB Sud; Groupement Hospitalier Sud/ Hospices Civils de Lyon; Pierre-Bénite France
| | - P. Dartigues
- Département de Biologie et Pathologie Médicales - Service de pathologie Morphologique; Gustave Roussy; Villejuif France
| | - J. Dupuis
- Unité Hémopathies Lymphoïdes; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - B. Ghaleh
- Plateforme de Ressources Biologiques; APHP - Hôpitaux Universitaires Henri Mondor; Créteil France
| | - P. Gravelle
- Pathology and Cytology Department; UMR1037 Centre de Recherche en Cancerologie de Toulouse, CHU Toulouse, IUCT Oncopole / Toulouse III Paul Sabatier University / Inserm; Toulouse France
| | - R. Houot
- Hématologie; CHU Rennes - Pontchaillou; RENNES France
| | | | - C. Laurent
- Pathology and Cytology Department; UMR1037 Centre de Recherche en Cancerologie de Toulouse, CHU Toulouse, IUCT Oncopole / Toulouse III Paul Sabatier University / Inserm; Toulouse France
| | - J. Moreaux
- Hématologie Biologique; CHU Montpellier; Montpellier France
| | - C. Pangault
- UMR-S 1236 / Laboratoire Hématologie; Université de Rennes I / CHU Rennes; Rennes France
| | - V. Ribrag
- Laboratoire RT Hématologie (AMMICa INSERM US23/CNRS UMS3655); Gustave Roussy; Villejuif France
| | - G. Salles
- Hématologie Clinique; Hospices Civils de Lyon / Université Claude Bernard; Pierre Bénite France
| | - V. Szablewski
- Pathologie et Oncobiologie; CHU Montpellier; Montpellier France
| | - V. Thouault
- Laboratoire d'hématologie; CHU Rennes - Pontchaillou; Rennes France
| | - G. Uze
- UMR 5235; CNRS / University Montpellier; Montpellier France
| | - V. Verge
- Département de Biologie et Pathologie Médicales - Laboratoire d'hématologie; Gustave Roussy; Villejuif France
| | - L. Ysebaert
- Hématologie; IUC-Toulouse Oncopole; Toulouse France
| | - P. Gaulard
- Department of Pathology; AP-HP; Créteil France
| | - T. Fest
- UMR-S 1236 / Laboratoire Hématologie; Université de Rennes I / CHU Rennes; Rennes France
| |
Collapse
|
29
|
Xiao R, Zhu L, Su Y, Zhang J, Lu Y, Li J, Wang T, Fang J, Jing ZC, Dupuis J, Luo S, Hu Q. Monocrotaline pyrrole induces pulmonary endothelial damage through binding to and release from erythrocytes in lung during venous blood reoxygenation. Am J Physiol Lung Cell Mol Physiol 2019; 316:L798-L809. [PMID: 30785344 DOI: 10.1152/ajplung.00279.2018] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Monocrotaline has been widely used to establish an animal model of pulmonary hypertension, most frequently in rats. An important feature of this model resides in the selectivity of monocrotaline injury toward the pulmonary vascular endothelium versus the systemic vasculature when administrated at standard dosage. The toxic metabolite of monocrotaline, monocrotaline pyrrole, is transported by erythrocytes. This study aimed to reveal whether partial pressure of oxygen of blood determined the binding and release of monocrotaline pyrrole from erythrocytes in rats with one subcutaneous injection of monocrotatline at the standard dosage of 60 mg/kg. Our experiments demonstrated that monocrotaline pyrrole bound to and released from erythrocytes at the physiological levels of partial pressure of oxygen in venous and arterial blood, respectively, and then aggregated on pulmonary artery endothelial cells. Monocrotaline pyrrole-induced damage of endothelial cells was also dependent on partial pressure of oxygen. In conclusion, our results demonstrate the importance of oxygen partial pressure on monocrotaline pyrrole binding to erythrocytes and on aggregation and injury of pulmonary endothelial cells. We suggest that these mechanisms contribute to pulmonary selectivity of this toxic injury model of pulmonary hypertension.
Collapse
Affiliation(s)
- Rui Xiao
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Liping Zhu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yuan Su
- Key Laboratory of Pulmonary Diseases of Ministry of Health, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Respiratory Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jiwei Zhang
- Key Laboratory of Pulmonary Diseases of Ministry of Health, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yankai Lu
- Key Laboratory of Pulmonary Diseases of Ministry of Health, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jiansha Li
- Key Laboratory of Pulmonary Diseases of Ministry of Health, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Tao Wang
- Key Laboratory of Pulmonary Diseases of Ministry of Health, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Respiratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jing Fang
- Department of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan China
| | - Zhi-Cheng Jing
- State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China
| | - Jocelyn Dupuis
- Montreal Heart Institute, Montreal, Quebec, Canada.,Department of Medicine, Université de Montréal , Montreal, Quebec , Canada
| | - Shengquan Luo
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Qinghua Hu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
30
|
Nasri A, Dupuis J, Hausermann L, Tremblay-Gravel M, Parent M, Carrier M, Racine N, de Denus S, Ducharme A, Fortier A, White M. Secular Trends and Outcome of Isolated versus Combined Type 2 Pulmonary Hypertension in Patients with End-Stage Heart Failure. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.1237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
31
|
Gilles F, Damy T, Bodez D, Galat A, Guendouz S, Dubois-Rande J, Issaurat P, Bézard M, Oghina S, Kharoubi M, Frenkel V, Mokhri A, Lebras F, Beladj K, Dupuis J. Effect on mortality of combined or sequential chemotherapy in patients with cardiac light-chain amyloidosis. Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2018.10.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Dolidon S, Melloni B, Chabot J, Foret D, Dupuis J, Tesnier E, Petit G, Muir J, Cuvelier A, Patout M. Analyse d’une base de données nationale de dysfonctionnements de ventilateurs de domicile. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Alonso Martinez LM, Harel F, Nguyen QT, Létourneau M, D'Oliviera-Sousa C, Meloche B, Finnerty V, Fournier A, Dupuis J, DaSilva JN. Al[ 18F]F-complexation of DFH17, a NOTA-conjugated adrenomedullin analog, for PET imaging of pulmonary circulation. Nucl Med Biol 2018; 67:36-42. [PMID: 30388434 DOI: 10.1016/j.nucmedbio.2018.10.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Revised: 10/01/2018] [Accepted: 10/11/2018] [Indexed: 01/06/2023]
Abstract
INTRODUCTION Adrenomedullin receptors are highly expressed in human alveolar capillaries and provide a molecular target for imaging the integrity of pulmonary microcirculation. In this work, we aimed to develop a NOTA-derivatized adrenomedullin analog (DFH17), radiolabeled with [18F]AlF, for PET imaging of pulmonary microcirculation. METHODS Highly concentrated [18F](AlF)2+ (15 μL) was produced from purified fluorine-18 in NaCl 0.9%. Various complexation experiments were carried out at Al-to-NOTA molar ratios ranging from 1:1 to 1:40 to assess optimal radiolabeling conditions before using the peptide. DFH17 peptide (2 mM, pH 4) was radiolabeled with [18F](AlF)2+ for 15 min at 100 °C in a total volume of 60 μL. As part of the radiolabeling process, parameters such as fluorine-18 activity (~37 and 1480 MBq), concentration of AlCl3 (0.75, 2, 3, 6 or 10 mM) and the effects of hydrophilic organic solvent (aqueous vs ethanol 50%) were studied. The final formulation was tested for purity, identity and stability in saline. Initial in vivo evaluation of [18F]AlF-DFH17 was performed in normal rats by PET/CT. RESULTS The scaled-up production of [18F]AlF-DFH17 was performed in high radiochemical and chemical purities in an overall radiochemical yield of 22-38% (at end-of-synthesis) within 60 min. The final formulation was stable in saline at different radioactive concentrations for 8 h. PET evaluation in rats revealed high lung-to-background ratios and no defluorination in vivo up to 1 h post-injection. CONCLUSION The novel radioconjugate [18F]AlF-DFH17 appears to be a promising PET ligand for pulmonary microcirculation imaging.
Collapse
Affiliation(s)
- Luis Michel Alonso Martinez
- University of Montreal Hospital Research Centre, 900 rue Saint-Denis, Montréal, Québec H2X 3H8, Canada; Department of Biomedical Engineering, Faculty of Medicine, Université de Montréal, Pavillon Paul-G. Desmarais, 2960 chemin de la Tour, Montréal, Québec H3T 1J4, Canada; Research Center of the Montreal Heart Institute, 5000 Rue Bélanger, Montréal, Québec H1T 1C8, Canada
| | - François Harel
- Department of Biomedical Engineering, Faculty of Medicine, Université de Montréal, Pavillon Paul-G. Desmarais, 2960 chemin de la Tour, Montréal, Québec H3T 1J4, Canada; Research Center of the Montreal Heart Institute, 5000 Rue Bélanger, Montréal, Québec H1T 1C8, Canada; Department of Radiology, Radio-oncology and Nuclear Medicine, Université de Montréal, Pavillon Roger-Gaudry, 2900 Boulevard Edouard Montpetit, Montréal, Québec H3T 1J4, Canada
| | - Quang T Nguyen
- Research Center of the Montreal Heart Institute, 5000 Rue Bélanger, Montréal, Québec H1T 1C8, Canada
| | - Myriam Létourneau
- Laboratoire D'études Moléculaires et Pharmacologiques des Peptides, INRS-Institut Armand-Frappier, 531 boulevard des Prairies, Laval, Québec H7V 1B7, Canada
| | - Caroline D'Oliviera-Sousa
- Research Center of the Montreal Heart Institute, 5000 Rue Bélanger, Montréal, Québec H1T 1C8, Canada
| | - Bernard Meloche
- Research Center of the Montreal Heart Institute, 5000 Rue Bélanger, Montréal, Québec H1T 1C8, Canada
| | - Vincent Finnerty
- Research Center of the Montreal Heart Institute, 5000 Rue Bélanger, Montréal, Québec H1T 1C8, Canada
| | - Alain Fournier
- Department of Radiology, Radio-oncology and Nuclear Medicine, Université de Montréal, Pavillon Roger-Gaudry, 2900 Boulevard Edouard Montpetit, Montréal, Québec H3T 1J4, Canada
| | - Jocelyn Dupuis
- Research Center of the Montreal Heart Institute, 5000 Rue Bélanger, Montréal, Québec H1T 1C8, Canada; Department of Medicine, Université de Montréal, 2900 boulevard Edouard Montpetit, Montréal, Québec H3T 1J4, Canada
| | - Jean N DaSilva
- University of Montreal Hospital Research Centre, 900 rue Saint-Denis, Montréal, Québec H2X 3H8, Canada; Department of Biomedical Engineering, Faculty of Medicine, Université de Montréal, Pavillon Paul-G. Desmarais, 2960 chemin de la Tour, Montréal, Québec H3T 1J4, Canada; Department of Radiology, Radio-oncology and Nuclear Medicine, Université de Montréal, Pavillon Roger-Gaudry, 2900 Boulevard Edouard Montpetit, Montréal, Québec H3T 1J4, Canada.
| |
Collapse
|
34
|
Wu WH, Yuan P, Zhang SJ, Jiang X, Wu C, Li Y, Liu SF, Liu QQ, Li JH, Pudasaini B, Hu QH, Dupuis J, Jing ZC. Impact of Pituitary-Gonadal Axis Hormones on Pulmonary Arterial Hypertension in Men. Hypertension 2018; 72:151-158. [PMID: 29712743 DOI: 10.1161/hypertensionaha.118.10963] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Revised: 02/19/2018] [Accepted: 04/03/2018] [Indexed: 11/16/2022]
Abstract
The association of sex hormone (estradiol, testosterone, and progesterone) with cardiopulmonary disease has already attracted great attention, especially in pulmonary arterial hypertension (PAH). However, the impact of sex hormones and their pituitary stimulators (follicle-stimulating hormone and luteinizing hormone) on PAH in men remains unclear. We conducted a prospective cohort study recruiting 95 patients with idiopathic PAH from 2008 to 2014 and following up for a median of 65 months for death. Compared with control, abnormal plasma levels of sex hormones were more common in patients with PAH. Higher estradiol and estradiol/testosterone levels were associated with risk of PAH diagnosis (odds ratio per ln estradiol, 3.55; P<0.001; odds ratio per ln estradiol/testosterone, 4.30; P<0.001), whereas higher testosterone and progesterone were associated with a reduced risk (odds ratio per ln testosterone, 0.48; P=0.003; odds ratio per ln progesterone, 0.09; P<0.001). Fifty patients died during follow-up. Men with higher estradiol had increased mortality (hazard ratio per ln estradiol, 2.02; P=0.007), even after adjustment for baseline characteristics and PAH treatment. According to receiver operating characteristic analysis, patients with PAH with higher estradiol level (≥145.55 pmol/L) had worse 5-year survival rate compared with those with lower estradiol (38.6% versus 68.2%; log-rank test P=0.001). Therefore, our data show higher estradiol, estradiol/testosterone ratio, lower testosterone, and progesterone were associated with increased risk of PAH. Meanwhile, higher estradiol was independently associated with higher mortality in men with PAH. Further studies are needed to explain the origin of these hormonal derangements and their potential pathophysiological implications in PAH.
Collapse
Affiliation(s)
- Wen-Hui Wu
- From the Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China (W.-H.W., P.Y., S.-J.Z., Y.L., B.P.)
| | - Ping Yuan
- From the Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China (W.-H.W., P.Y., S.-J.Z., Y.L., B.P.)
| | - Si-Jin Zhang
- From the Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China (W.-H.W., P.Y., S.-J.Z., Y.L., B.P.)
| | - Xin Jiang
- State Key Laboratory of Cardiovascular Disease, FuWai Hospital, and Key Laboratory of Pulmonary Vascular Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing (X.J., S.-F.L., Q.-Q.L., J.-H.L., Z.-C.J.)
| | - Cheng Wu
- Department of Health Statistics, Second Military Medical University, Shanghai, China (C.W.)
| | - Yuan Li
- From the Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China (W.-H.W., P.Y., S.-J.Z., Y.L., B.P.)
| | - Shao-Fei Liu
- State Key Laboratory of Cardiovascular Disease, FuWai Hospital, and Key Laboratory of Pulmonary Vascular Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing (X.J., S.-F.L., Q.-Q.L., J.-H.L., Z.-C.J.)
| | - Qian-Qian Liu
- State Key Laboratory of Cardiovascular Disease, FuWai Hospital, and Key Laboratory of Pulmonary Vascular Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing (X.J., S.-F.L., Q.-Q.L., J.-H.L., Z.-C.J.)
| | - Jing-Hui Li
- State Key Laboratory of Cardiovascular Disease, FuWai Hospital, and Key Laboratory of Pulmonary Vascular Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing (X.J., S.-F.L., Q.-Q.L., J.-H.L., Z.-C.J.)
| | - Bigyan Pudasaini
- From the Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China (W.-H.W., P.Y., S.-J.Z., Y.L., B.P.)
| | - Qing-Hua Hu
- Department of Pathophysiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China (Q.-H.H.)
| | - Jocelyn Dupuis
- Montreal Heart Institute Research Center, Université de Montréal, Québec, Canada (J.D.)
| | - Zhi-Cheng Jing
- State Key Laboratory of Cardiovascular Disease, FuWai Hospital, and Key Laboratory of Pulmonary Vascular Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing (X.J., S.-F.L., Q.-Q.L., J.-H.L., Z.-C.J.)
| |
Collapse
|
35
|
Dupuis J, Nguyen QT, Sirois MG, Calderone A, Tardif JC, Shi Y, Laverdure A, Grouix B, Gagnon L. PBI-4050, A NOVEL FIRST-IN-CLASS AGENT, REDUCES PULMONARY HYPERTENSION, LUNG REMODELING AND RIGHT VENTRICULAR DYSFUNCTION IN HEART FAILURE. J Am Coll Cardiol 2018. [DOI: 10.1016/s0735-1097(18)31207-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
36
|
Dupuis J, Moreau M, Daminet S, Hébert P, Grisneaux E, Charette B. Assessing the efficacy of long-term administration of Tolfenamic acid in dogs undergoing femoral head and neck excision. Vet Comp Orthop Traumatol 2018. [DOI: 10.1055/s-0038-1632785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryFemoral head and neck excision (FHNE) is a salvage procedure routinely performed when severe osteoarthritis is present and clinical signs cannot be managed by conservative treatment, or when total hip replacement is cost prohibitive for the owners. The purpose of the study reported herein was to evaluate the adverse effects and efficacy of long-term administration of Tolfenamic acid in dogs undergoing FHNE. Twenty dogs admitted with clinical signs associated with bilateral hip degenerative joint disease and weighing more than 20 kg were included in the study. Ten dogs received Tolfenamic acid for four months following FHNE and 10 dogs received a placebo. At four months after surgery, the placebo group had a significant decrease, compared with pre-operative values, in peak vertical force (PVF) (60.38% BW vs 64.77% BW, p = 0.046), and a significant decrease in vertical impulse (VI) (8.38% BW x sec. vs 9.64% BW x sec., p = 0.023). There was not any significant difference between pre- and post-operative results in the Tolfenamic acid group regarding PVF (65.13% BW vs 63.31% BW, p = 0.296) and VI (8.24% BW x sec. vs 8.71% BW x sec., p = 0.945). A significant difference was not found between the two groups with regard to endoscopic evaluation of mucosal lesions. Subjectively, the owners of the dogs in the Tolfenamic acid group reported an earlier use of the limb, a more compliant dog during physical therapy and a more rapid return to a ‘normal’ gait. Long-term administration of Tolfenamic acid may therefore be recommended, following FHNE, to improve the results of the operation.
Collapse
|
37
|
Dupuis J, Beauregard G, Bonneau NH, Breton L, Planté J. Long-term Results of Conservative Treatment, Excision Arthroplasty and Triple Pelvic Osteotomy for the Treatment of Hip Dysplasia in the Immature Dog. Vet Comp Orthop Traumatol 2018. [DOI: 10.1055/s-0038-1632578] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThe efficiency of conservative treatment, excision arthroplasty of the femoral head and neck and triple pelvic osteotomy for the treatment of hip dysplasia in the immature dog were compared using locomotor, physical and radiographic examinations and owner’s evaluation. Cases selected for this study were dogs diagnosed with bilateral hip dysplasia, initially admitted with clinical signs (lameness, pain), immature at the beginning of the treatment (less than 12 months of age), with both hips subjected to the same treatment (conservative treatment, excision arthroplasty of the femoral head and neck or triple pelvic osteotomy). These dogs never showed any musculoskeletal problems other than hip dysplasia and the surgical treatment had been completed at least 20 months prior to re-evaluation time. Fourteen hips were re-evaluated in the conservative group, 16 in the triple pelvic osteotomy group and ten in the excision arthroplasty group. Locomotor, physical and owner’s evaluations demonstrated the superiority of the triple pelvic osteotomy. These evaluations also showed that excision arthroplasty was more efficient than conservative treatment. Radiographic examination demonstrated the obvious superiority of the triple pelvic osteotomy over conservative treatment.Locomotor, physical and owner’s evaluations demonstrated the superiority of the triple pelvic osteotomy over conservative treatment and excision arthroplasty for the treatment of hip dysplasia in the immature dog. Radiographic examination demonstrated the obvious superiority of the triple pelvic osteotomy over conservative treatment for joint congruence and control of degenerative joint disease.
Collapse
|
38
|
Dupuis J, Beauregard G, Bonneau NH, Breton L, Planté J. Long-term Results of Conservative Treatment, Excision Arthroplasty and Triple Pelvic Osteotomy for the Treatment of Hip Dysplasia in the Immature Dog. Vet Comp Orthop Traumatol 2018. [DOI: 10.1055/s-0038-1632583] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThe long-term efficiency of conservative treatment, excision arthroplasty of the femoral head and neck and triple pelvic osteotomy for the treatment of hip dysplasia in the immature dog were compared using ground reaction forces analysis at the trot. Fourteen hips were re-evaluated for the conservative treatment group, 16 for the triple pelvic osteotomy group and ten for the excision arthroplasty group. Force plate analysis demonstrated that hind limbs belonging to the triple pelvic osteotomy group had, at the trot, a locomotor function similar to the one of normal hind limbs in the control group. At a “similar age”, hind limbs of the conservative group did not show any marked difference from those in the triple pelvic osteotomy and control groups. The dogs of the excision arthroplasty group showed ground reaction forces abnormalities, most probably due to the absence of a coxofemoral joint (decreased peak propulsive force and Fz impulse, compared to triple pelvic osteotomy and control groups). The forelimbs of conservative treatment, excision arthroplasty and triple pelvic osteotomy groups showed a peak propulsive force superior to the one in the control group. This could be an adaptation phenomenon in order to compensate a deficient function of the hind limbs or a habit acquired at a younger age.Force plate analysis has demonstrated that hind limbs treated bilaterally with triple pelvic osteotomy had, at the trot, a locomotor function similar to the one of normal hind limbs from a control group. At a mean age of 4.5 ± 1 years, dogs treated conservatively did not show, at the trot, any marked difference with those treated with triple pelvic osteotomy and with normal dogs. Hind limbs treated with excision arthroplasty showed certain abnormalities most probably due to the absence of a coxofemoral joint such as a significant decrease of peak propulsive force and Fz impulse.
Collapse
|
39
|
Dupuis J, Beauregard G, Breton L, Paré J, Charette B. Palpation and dorsal acetabular rim radiographic view for early detection of canine hip dysplasia. Vet Comp Orthop Traumatol 2018. [DOI: 10.1055/s-0038-1632686] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThe objectives of this study were to standardize a palpation technique and to determine within and between examiners, the repeatability in interpreting the angle of reduction, subluxation and the acetabular slope measurements. Also it was desired to ascertain the effect of pelvis positioning on the acetabular slope measurement on sixmonth- old dogs. On palpation examination fifty-three (53) dogs had their angles of reduction and subluxation measured. A radiographic examination including a standard hip-extended view, a compression and a distraction view and a dorsal acetabular rim view were performed on each dog.The within examiner repeatability was excellent for both the angle of reduction and subluxation (r = 0.975, p = 0.82 and r = 0.977, p = 0.81 respectively). The between examiners repeatability was good for the angle of reduction (r = 0.843, p = 0.51) but only a fair correlation was found for the angle of subluxation (r = 0.652, p = 0.83). For the acetabular slope measurement, an excellent within examiner correlation was observed (r = 0.940, p = 0.52). However, though a good correlation was found between examiners, a significant difference was found in the measurements of the three examiners (r = 0.780, p < 0.0001). The under- or overrotation position slightly changed the slope measurement but a fair correlation was still observed with the perfect position (r = 0.769, p = 0.074 and r = 0.684, p = 0.061 respectively). If the pelvis is turned to one side, a correlation was not found (r = 0.090, p = 0.847). The high repeatability of the angle of reduction measurement in six-month-old dogs suggests that it may be used by multiple examiners, with the expectation of comparable and consistent results. The modified method of the acetabular slope measurement improved the correlation, but a significant difference was still observed between examiners.Early detection in life of canine hip dysplasia is important. The angle of reduction and the acetabular slope have been evaluated as diagnostic tools. With regard to its repeatability between examiners, the use of the angle of reduction by multiple examiners will be acceptable. The correlation between examiners in the acetabular slope measurement was good but a significant difference was present. Part two is now being analyzed.
Collapse
|
40
|
Blackketter D, Harari J, Dupuis J. Biomechanical Properties of the Stifle Joint Lateral Collateral Ligament in Dogs. Vet Comp Orthop Traumatol 2018. [DOI: 10.1055/s-0038-1633103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Bone/lateral collateral ligament/bone preparations were tested and structural mechanical properties compared to properties of cranial cruciate ligament in 15 dogs. The lateral collateral ligament has sufficient stiffness to provide stifle joint stability and strength to resist acute overload following fibular head transposition.
Collapse
|
41
|
Adamski H, Ingen‐Housz‐Oro S, Machet L, Carriou A, Ram‐Wolff C, Ortonne N, Le Gall F, Durlach A, Dupuis J, Dauriac C, Dupuy A, Grange F, Bagot M. Lymphomatoid papulosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: three cases. Br J Dermatol 2017; 178:e5-e6. [DOI: 10.1111/bjd.15698] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- H. Adamski
- Department of Dermatology Rennes University Hospital Rennes France
| | | | - L. Machet
- Department of Dermatology Tours University Hospital and François Rabelais University Tours France
| | - A.C. Carriou
- Department of Dermatology Rennes University Hospital Rennes France
| | - C. Ram‐Wolff
- Department of Dermatology AP‐HP St Louis Hospital Paris 7 University Paris France
| | - N. Ortonne
- Department of Pathology AP‐HP Henri Mondor Hospital Creteil France
| | - F. Le Gall
- Department of Pathology Rennes University Hospital Rennes France
| | - A. Durlach
- Laboratory of Histopathology Reims University Hospital Reims France
| | - J. Dupuis
- Lymphoid Malignancies Unit AP‐HP Henri Mondor Hospital Creteil France
| | - C. Dauriac
- Department of Hematology Rennes University Hospital Rennes France
| | - A. Dupuy
- Department of Dermatology Rennes University Hospital Rennes France
| | - F. Grange
- Department of Dermatology Reims University Hospital Reims France
| | - M. Bagot
- Department of Dermatology AP‐HP St Louis Hospital Paris 7 University Paris France
| |
Collapse
|
42
|
Cossette S, Côté J, Rouleau G, Robitaille M, Heppell S, Mailhot T, Fontaine G, Cournoyer C, Gagnon MP, Gallani MC, Tanguay JF, Dupuis J, Nigam A, Guertin MC. A Web-Based Tailored Intervention to Support Illness Management in Patients With an Acute Coronary Syndrome: Pilot Study. JMIR Cardio 2017; 1:e4. [PMID: 31758758 PMCID: PMC6834220 DOI: 10.2196/cardio.7342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Revised: 07/06/2017] [Accepted: 07/12/2017] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Illness management after an acute coronary syndrome (ACS) is crucial to prevent cardiac complications, to foster participation in a cardiac rehabilitation (CR) program, and to optimize recovery. Web-based tailored interventions have the potential to provide individualized information and counseling to optimize patient's illness management after hospital discharge. OBJECTIVE We aimed to assess the feasibility and acceptability of a Web-based tailored intervention (TAVIE@COEUR) designed to improve illness management in patients hospitalized for an ACS. Illness management outcomes were operationalized by self-care, medication adherence, anxiety management, cardiac risk factors reduction, and enrollment in a CR program. METHODS This posttest pilot study was conducted with one group (N=30) of patients hospitalized for an ACS on the coronary care unit of a tertiary cardiology center. TAVIE@COEUR comprises three Web-based sessions, with a duration ranging from 10 to 45 min and is structured around an algorithm to allow the tailoring of the intervention to different pathways according to patients' responses to questions. TAVIE@COEUR includes 90 pages, 85 videos, and 47 PDF documents divided across session 1 (S1), session 2 (S2), and session 3 (S3). These sessions concern self-care and self-observation skills related to medication-taking (S1), emotional control and problem-solving skills (S2), and social skills and interacting with health professionals (S3). Throughout the videos, a virtual nurse (providing the intervention virtually) guides the participants in the acquisition of self-care skills. Patients completed S1 of TAVIE@COEUR before hospital discharge and were asked to complete S2 and S3 within 2 weeks after discharge. Feasibility indicators were extracted from the TAVIE@COEUR system. Data regarding acceptability (satisfaction and appreciation of the platform) and preliminary effect (self-care, medication adherence, anxiety management, risk factor reduction, and CR enrollment) were assessed through questionnaires at 1 month following discharge. Preliminary effect was assessed by comparing baseline and 1-month illness management variables. RESULTS Of the 30 participants, 20 completed S1, 10 completed S2, and 5 completed S3. Good acceptability scores were observed for ease of navigation (mean=3.58, standard deviation [SD]=0.70; scale=0-4), ease of understanding (mean=3.46, SD=0.63; scale=0-4), and applicability (mean=3.55, SD=0.74; scale=0-4). The lowest acceptability scores were observed for information tailoring (mean=2.93, SD=0.68; scale=0-4) and individual relevance (mean=2.56, SD=0.96; scale=0-4). With regard to preliminary effect, we observed an overall self-care at 1 month following discharge score higher than at baseline (mean at 1 month=54.07, SD=3.99 vs mean at baseline=49.09, SD=6.92; scale-0-60). CONCLUSIONS Although participants reported general satisfaction and appreciation of TAVIE@COEUR, acceptability and feasibility results show the need for further development of the Web-based intervention to enhance its tailoring before undertaking a full-fledged randomized controlled trial. This may be accomplished by optimizing the adaptability of TAVIE@COEUR to patients' knowledge, needs, interests, individual capabilities, and emotional and cognitive responses during session completion.
Collapse
Affiliation(s)
- Sylvie Cossette
- Montreal Heart Institute Research Center, Montréal, QC, Canada.,Faculty of Nursing, Université de Montréal, Montréal, QC, Canada
| | - José Côté
- Faculty of Nursing, Université de Montréal, Montréal, QC, Canada.,Research Center of the Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.,Research Chair in Innovative Nursing Practices, Montréal, QC, Canada
| | - Geneviève Rouleau
- Research Center of the Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.,Research Chair in Innovative Nursing Practices, Montréal, QC, Canada.,Faculty of Nursing, Laval University, Quebec City, QC, Canada
| | | | - Sonia Heppell
- Faculty of Nursing, Université de Montréal, Montréal, QC, Canada.,Montreal Heart Institute, Montreal, QC, Canada
| | - Tanya Mailhot
- Montreal Heart Institute Research Center, Montréal, QC, Canada.,Faculty of Nursing, Université de Montréal, Montréal, QC, Canada
| | - Guillaume Fontaine
- Montreal Heart Institute Research Center, Montréal, QC, Canada.,Faculty of Nursing, Université de Montréal, Montréal, QC, Canada
| | | | | | | | - Jean-Francois Tanguay
- Montreal Heart Institute Research Center, Montréal, QC, Canada.,Faculty of Medicine, Université de Montréal, Montréal, QC, Canada
| | - Jocelyn Dupuis
- Montreal Heart Institute Research Center, Montréal, QC, Canada.,Faculty of Medicine, Université de Montréal, Montréal, QC, Canada
| | - Anil Nigam
- Montreal Heart Institute Research Center, Montréal, QC, Canada
| | | |
Collapse
|
43
|
Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L. Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. Am J Respir Crit Care Med 2017; 195:1661-1670. [PMID: 28430547 PMCID: PMC5476915 DOI: 10.1164/rccm.201701-0150ws] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Accepted: 04/18/2017] [Indexed: 12/18/2022] Open
Abstract
The Division of Lung Diseases of the NHLBI and the Cardiovascular Medical Education and Research Fund held a workshop to discuss how to leverage the anticipated scientific output from the recently launched "Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics" (PVDOMICS) program to develop newer approaches to pulmonary vascular disease. PVDOMICS is a collaborative, protocol-driven network to analyze all patient populations with pulmonary hypertension to define novel pulmonary vascular disease (PVD) phenotypes. Stakeholders, including basic, translational, and clinical investigators; clinicians; patient advocacy organizations; regulatory agencies; and pharmaceutical industry experts, joined to discuss the application of precision medicine to PVD clinical trials. Recommendations were generated for discussion of research priorities in line with NHLBI Strategic Vision Goals that include: (1) A national effort, involving all the stakeholders, should seek to coordinate biosamples and biodata from all funded programs to a web-based repository so that information can be shared and correlated with other research projects. Example programs sponsored by NHLBI include PVDOMICS, Pulmonary Hypertension Breakthrough Initiative, the National Biological Sample and Data Repository for PAH, and the National Precision Medicine Initiative. (2) A task force to develop a master clinical trials protocol for PVD to apply precision medicine principles to future clinical trials. Specific features include: (a) adoption of smaller clinical trials that incorporate biomarker-guided enrichment strategies, using adaptive and innovative statistical designs; and (b) development of newer endpoints that reflect well-defined and clinically meaningful changes. (3) Development of updated and systematic variables in imaging, hemodynamic, cellular, genomic, and metabolic tests that will help precisely identify individual and shared features of PVD and serve as the basis of novel phenotypes for therapeutic interventions.
Collapse
Affiliation(s)
- John H. Newman
- Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt Medical Center, Nashville, Tennessee
| | - Stuart Rich
- Division of Cardiology, Department of Medicine, Northwestern University, Chicago, Illinois
| | - Steven H. Abman
- Pediatric Heart and Lung Center, University of Colorado, Aurora, Colorado
| | | | | | | | - Raymond L. Benza
- Department of Cardiovascular Disease, Allegheny Health Network, Pittsburgh, Pennsylvania
| | - Todd M. Bull
- Division of Pulmonary and Critical Care Medicine and
| | - Stephen Y. Chan
- Division of Cardiology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| | | | | | - Jocelyn Dupuis
- Department of Medicine, University of Montreal, Montreal, Quebec, Canada
| | - Serpil C. Erzurum
- Department of Pathobiology, and
- Department of Medicine, Cleveland Clinic, Cleveland, Ohio
| | | | - Mark Geraci
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Indiana University, Indianapolis, Indiana
| | - Hunter Gillies
- Independent Consultant and Pharmaceutical Physician, Half Moon Bay, California
| | - Mark Gladwin
- Division of Cardiology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| | | | - Anna R. Hemnes
- Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt Medical Center, Nashville, Tennessee
| | - Roy S. Herbst
- Division of Medical Oncology, Department of Medicine, Yale University, New Haven, Connecticut
| | | | - Nicholas S. Hill
- Division of Pulmonary, Critical Care, and Sleep Medicine, Tufts University, Boston, Massachusetts
| | - Evelyn M. Horn
- Division of Cardiology, Cornell University, New York, New York
| | - Kendall Hunter
- College of Engineering and Applied Science, University of Colorado, Denver, Colorado
| | - Zhi-Cheng Jing
- FuWai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
| | - Roger Johns
- Department of Anesthesiology and Critical Care and
| | | | - Steven M. Kawut
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Tim Lahm
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Indiana University, Indianapolis, Indiana
| | - Jane A. Leopold
- Division of Cardiology, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
| | - Greg D. Lewis
- Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts
| | - Stephen C. Mathai
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Vallerie V. McLaughlin
- Division of Cardiology, Department of Medicine, University of Michigan, Ann Arbor, Michigan
| | | | - Steven D. Nathan
- Advanced Lung Disease Program, Inova Fairfax Hospital, Falls Church, Virginia
| | - William Nichols
- Department of Human Genetics, Cincinnati Children’s Hospital, Cincinnati, Ohio
| | | | - Marlene Rabinovitch
- Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Stanford, California
| | - Jonathan Rich
- Division of Cardiology, Department of Medicine, Northwestern University, Chicago, Illinois
| | - Franz Rischard
- Division of Cardiology, University of Arizona, Tucson, Arizona
| | - Sharon Rounds
- Department of Medicine and Laboratory Medicine, Brown University, Providence, Rhode Island
| | - Sanjiv J. Shah
- Division of Cardiology, Department of Medicine, Northwestern University, Chicago, Illinois
| | - Victor F. Tapson
- Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, California
| | - Naomi Lowy
- Division of Cardiovascular and Renal Products, Food and Drug Administration, Office of Drug Evaluation I, Office of New Drugs, Food and Drug Administration Silver Spring, Maryland; and
| | - Norman Stockbridge
- Division of Cardiovascular and Renal Products, Food and Drug Administration, Office of Drug Evaluation I, Office of New Drugs, Food and Drug Administration Silver Spring, Maryland; and
| | - Gail Weinmann
- Division of Lung Diseases, NHLBI, National Institutes of Health, Bethesda, Maryland
| | - Lei Xiao
- Division of Lung Diseases, NHLBI, National Institutes of Health, Bethesda, Maryland
| |
Collapse
|
44
|
Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Cartron G, Schmitt A, Houot R, Dartigeas C, Pignon J, Corm S, Bannos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Karlin L, Damaj G, Feugier P, Fornecker L, Chabrot C, Ysebaert I, Callanan M, Le Gouill S. FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_131] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- R. Gressin
- Onco-Hematology; University Hospital; Grenoble France
| | | | | | - A. Moreau
- Pathology; University Hospital; Nantes France
| | - S. Carras
- Onco-Hematology; University Hospital; Grenoble France
| | - G. Cartron
- Hematology; Hospital University; Montpellier France
| | - A. Schmitt
- Hematology; Caner Center; Bordeaux France
| | - R. Houot
- Hematology; University Hospital; Rennes France
| | | | - J. Pignon
- Hematology, Hospital; Dunkerque France
| | - S. Corm
- Hematology, Hospital; Chambery France
| | - A. Bannos
- Hematology, Hospital; Bayonne France
| | - C. Mounier
- Hematology; Cancer Institute, St Priest en Jares; France
| | - J. Dupuis
- Hematology; University Hospital; Creteil France
| | - M. Macro
- Hematology; University Hospital; Caen France
| | - J. Fleury
- Hematology, Clinic; Clermont Ferrand France
| | - F. Jardin
- Hematology; Cancer Institute; Rouen France
| | - L. Karlin
- Hematology; University Hospital; France
| | - G. Damaj
- Hematology; University Hospital; Amiens France
| | - P. Feugier
- Hematology; University Hospital, Vandoeuvre Les Nancy; France
| | - L. Fornecker
- Hematology; University Hospital; Strasbourg France
| | - C. Chabrot
- Hematology; University Hospital; Clermont Ferrand France
| | - I. Ysebaert
- Hematology; University Hospital; Toulouse France
| | - M. Callanan
- INSERM U1209; Institute For Advanced Biosciences; La Tronche France
| | | |
Collapse
|
45
|
Bonnet C, Lamy T, Fruchart C, Legouill S, Gunzer K, Gastinne T, Jardin F, Karlin L, Houot R, Dupuis J, Tilly H, Salles G. IBRUTINIB IN ASSOCIATION WITH R-DHAP/OX FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA: PRELIMINARY RESULTS OF THE BIBLOS PHASE IB LYSA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C.M. Bonnet
- Clinical Hematology, Chu Liege; Angleur Belgium
| | - T. Lamy
- Hematology, Chu Rennes; Rennes France
| | - C. Fruchart
- Hematology; Centre François Baclesse Caen; Caen France
| | - S. Legouill
- Hematology, C.H.U. - Hotel Dieu; Nantes France
| | - K. Gunzer
- Hematology; Centre François Baclesse Caen; Caen France
| | - T. Gastinne
- Hematology, C.H.U. - Hotel Dieu; Nantes France
| | - F. Jardin
- Hematology; Centre Henri Becquerel; Rouen France
| | - L. Karlin
- Hematology; Centre Hospitalier Lyon-Sud, Pierre Benite; France
| | - R. Houot
- Hematology, Chu Rennes; Rennes France
| | - J. Dupuis
- Hematology; HU Henri Mondor Aphp, Creteil, Val-De-Marne; France
| | - H. Tilly
- Hematology; Centre Henri Becquerel; Rouen France
| | - G. Salles
- Hematology; Centre Hospitalier Lyon-Sud, Pierre Benite; France
| |
Collapse
|
46
|
Delfau-Larue M, Benmaad I, Robert P, Hamdane S, Nel I, Dupuis J, Haioun C, Berriolo Riedinger A, Casasnovas R, Itti E. BASELINE CIRCULATING CELL-FREE DNA LOAD IS RELATED TO, BUT ADDS PROGNOSTIC VALUE TO METABOLIC TUMOR BURDEN MEASURED BY FDG PET/CT IN FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M.H. Delfau-Larue
- Biological Hematology and Immunology Department, APHP; Groupe Hospitalier Mondor; Creteil France
| | - I. Benmaad
- Biological Hematology and Immunology Department, APHP; Groupe Hospitalier Mondor; Creteil France
| | - P. Robert
- Clinical hematology; Centre Hospitalier Universitaire-Dijon; Dijon France
| | - S. Hamdane
- Biological Hematology and Immunology Department, APHP; Groupe Hospitalier Mondor; Creteil France
| | - I. Nel
- Biological Hematology and Immunology Department, APHP; Groupe Hospitalier Mondor; Creteil France
| | - J. Dupuis
- Lymphoid Malignancies Unit, APHP; Groupe Hospitalier Mondor; Creteil France
| | - C. Haioun
- Lymphoid Malignancies Unit, APHP; Groupe Hospitalier Mondor; Creteil France
| | | | - R.O. Casasnovas
- Clinical hematology; Centre Hospitalier Universitaire-Dijon; Dijon France
| | - E. Itti
- Nuclear Medicine department, APHP; Groupe Hospitalier Mondor; Creteil France
| |
Collapse
|
47
|
Ghesquieres H, Tilly H, Sonet A, Dupuis J, Nicolas-Virelizier E, Andre M, Trullemans F, Eisenmann J, Delarue R, Fleck E, Morschhauser F, Blay J. THE 5-YEAR FOLLOW-UP RESULTS OF THE C5R PROTOCOL WITH RITUXIMAB AND INTRATHECAL LIPOSOMAL CYTARABINE FOR PRIMARY CNS LYMPHOMA: A PROSPECTIVE PHASE 2 STUDY OF THE LYSA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_61] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- H. Ghesquieres
- Hematology; Centre Hospitalier Lyon Sud; Pierre Benite France
| | - H. Tilly
- Hematology, Centre Henri Becquerel; Rouen France
| | - A. Sonet
- Hematology, CHU Dinant Godinne; Dinant Belgium
| | - J. Dupuis
- Hematology, CHU Henri Mondor; Creteil France
| | | | - M. Andre
- Hematology, CHU Dinant Godinne; Dinant Belgium
| | | | | | | | - E. Fleck
- Hematology, CH la Rochelle; La Rochelle France
| | | | - J. Blay
- Hematology, Centre Leon Berard; Lyon France
| |
Collapse
|
48
|
Cottereau A, Versari A, Dupuis J, Chartier L, Menga M, Casasnovas R, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, Salles G, Luminari S, Trotman J, Meignan M. PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: a POOLED ANALYSIS FROM LYSA AND FIL TRIALS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_105] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- A. Cottereau
- Nuclear Medicine Department; Tenon Hospital; Paris France
| | - A. Versari
- Nuclear Medicine Department; Santa Maria Nuova Hospital; Reggio Emilia Italy
| | - J. Dupuis
- Hematology Department, Lymphoid Malignancies Unit; Henri Mondor Hospital; Créteil France
| | - L. Chartier
- Department of Biostatistics; Centre Hospitalier Lyon Sud, Pierre Bénite, LYSARC; Pierre-Bénite France
| | - M. Menga
- Nuclear Medicine Department; Santa Maria Nuova Hospital; Reggio Emilia Italy
| | | | - C. Haioun
- Hematology Department, Lymphoid Malignancies Unit; Henri Mondor Hospital; Créteil France
| | - H. Tilly
- Hematology Department, UMR918, Centre Henri Becquerel; Université de Rouen; Rouen France
| | - V. Tarantino
- Nuclear Medicine Department; Santa Maria Nuova Hospital; Reggio Emilia Italy
| | - J. Dubreuil
- Nuclear Medicine Department, Centre Hospitalier Lyon Sud, Pierre Bénite; Pierre Benite France
| | - M. Federico
- Hematology; University of Modena and Reggio Emilia; Modena Italy
| | - G. Salles
- Hematology Department; Hospices Civils de Lyon 1, Université Claude Bernard Lyon 1; Pierre Benite France
| | - S. Luminari
- Hematology Department, Santa Maria Nuova Hospital, IRCCS; University of Modena and Reggio Emilia; Modena Italy
| | - J. Trotman
- Haematology Department, Concord Hospital; University of Sydney; Sydney Australia
| | - M. Meignan
- LYSA Imaging; Henri Mondor University Hospitals; Creteil France
| |
Collapse
|
49
|
|
50
|
Tchernonog E, Faurie P, Coppo P, Monjanel H, Bonnet A, Algarte Génin M, Mercier M, Dupuis J, Bijou F, Herbaux C, Delmer A, Fabiani B, Besson C, Le Gouill S, Gyan E, Laurent C, Ghesquieres H, Cartron G. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol 2017; 28:843-848. [PMID: 28031174 DOI: 10.1093/annonc/mdw684] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2016] [Indexed: 11/14/2022] Open
Abstract
Background Plasmablastic lymphoma (PBL), initially described in 1997 in the oral cavity of HIV positive patients, is now recognized as a distinct aggressive and rare entity of diffuse large B-cells lymphoma by the World Health Organization (WHO) classification. Since the original description, others cases have been reported. However, these are largely derived from case reports or small series limiting any definitive conclusions on clinical characteristics and outcome. Patients and methods The clinical, biological, pathological features and outcome of a cohort including 135 patients with PBL, from LYSA centers in France and Belgium, were reported and analyzed. Results The median age was 58 years, with a male predominance. The cohort was divided into 56 HIV-positive patients, 17 post-transplant patients and 62 HIV-negative/non-transplanted patients. Within HIV-negative/non-transplanted, a relative immunosuppression was found in most cases (systemic inflammatory disease, history of cancer, increased age associated with weakened immune system). We have also described a new subtype, PBL arising in a chronic localized inflammatory site, without any sign of immunosuppression. At presentation, 19% of patients showed oral involvement. Immunophenotype showed CD138 positivity in 88% of cases and CD20 negativity in 90% of cases. Chemotherapy was administered to 80% of patients, with a complete response (CR) rate of 55%. The median overall survival (OS) was 32 months. In univariate analysis, HIV positive status showed better OS when compared with HIV negative status. In multivariate analysis, International Prognostic Index score, chemotherapy and CR were associated with survival benefit. Conclusion(s) This cohort, the largest reported to date, increases the spectrum of knowledge on PBL, rarely described. However, specific guidelines to clarify treatment are lacking, and may improve the poor prognosis of this rare disease.
Collapse
Affiliation(s)
- E Tchernonog
- Department of Hematology, University Hospital of Montpellier, Montpellier, France
| | - P Faurie
- Department of Hematology, Léon Bérard Center, Lyon, France
| | - P Coppo
- Department of Hematology, Saint Antoine University Hospital, Paris, France
| | - H Monjanel
- Department of Hematology, University Hospital of Tours, Tours, France
| | - A Bonnet
- Department of Hematology, University Hospital of Nantes, Nantes, France
| | - M Algarte Génin
- Institute Pierre Louis of Epidemiology and Public Health, Paris, France
| | - M Mercier
- Department of Hematology, University Hospital of Angers, Angers, France
| | - J Dupuis
- Lymphoid Malignancies Unit University Hospital Henri Mondor, Créteil, France
| | - F Bijou
- Institute Bergonie, Bordeaux, France
| | - C Herbaux
- Department of Hematology, University Hospital of Lille, Lille, France
| | - A Delmer
- Department of Hematology, University Hospital of Reims, Reims, France
| | - B Fabiani
- Department of Biopathology, University Hospital Saint Antoine, Paris, France
| | - C Besson
- Department of Hematology, University Hospital Kremlin Bicêtre, Paris, France
| | - S Le Gouill
- Department of Hematology, University Hospital of Nantes, Nantes, France
| | - E Gyan
- Department of Hematology, University Hospital of Tours, Tours, France
| | - C Laurent
- Department of Biopathology, University Hospital of Toulouse, Toulouse, France
| | - H Ghesquieres
- Department of Hematology, University Hospital of Lyon Sud, Lyon, France, France
| | - G Cartron
- Department of Hematology, University Hospital of Montpellier, Montpellier, France
| |
Collapse
|